Unilife (UNIFF) 10-Q 9 Feb 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2016	Feb. 02, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	UNIS
Entity Registrant Name	Unilife Corp
Entity Central Index Key	1,476,170
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,147,033

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Current Assets:
Cash and cash equivalents	$ 9,309	$ 18,702
Restricted cash	2,700	2,400
Accounts receivable	2,914	374
Inventories	100	89
Prepaid expenses and other current assets	6,258	1,645
Total current assets	21,281	23,210
Property, plant and equipment, net	52,309	54,773
Goodwill	9,136	9,423
Other assets	256	255
Total assets	82,982	87,661
Current Liabilities:
Accounts payable	2,624	2,662
Accrued expenses	15,894	13,710
Current portion of long-term debt	702	669
Deferred revenue	5,160	1,660
Total current liabilities	24,380	18,701
Long-term debt, less current portion	125,403	104,445
Warrant liability	2,147	3,351
Derivative liability	457	347
Deferred revenue	48,047	47,550
Other long-term liabilities	640
Total liabilities	201,074	174,394
Contingencies (Note 11)
Stockholders’ Deficit:
Preferred stock, $0.01 par value, 50,000,000 shares authorized as of December 31, 2016; none issued and outstanding as of December 31, 2016 and June 30, 2016
Common stock, $0.01 par value, 350,000,000 shares authorized as of December 31, 2016; 17,441,917 and 17,488,032 shares issued, and 17,357,160 and 17,411,651 shares outstanding as of December 31, 2016 and June 30, 2016, respectively	174	175
Additional paid-in-capital	401,107	398,862
Accumulated deficit	(518,645)	(485,363)
Accumulated other comprehensive income	91	380
Treasury stock, at cost, 84,757 shares as of December 31, 2016 and 76,381 shares at June 30, 2016	(819)	(787)
Total stockholders’ deficit	(118,092)	(86,733)
Total liabilities and stockholders’ deficit	$ 82,982	$ 87,661

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Jun. 30, 2016
Statement Of Financial Position [Abstract]
Redeemable convertible preferred stock, Series A - subject to redemption, par value	$ 0.01	$ 0.01
Redeemable convertible preferred stock, Series A - subject to redemption, shares authorized	790	790
Redeemable convertible preferred stock, Series A - subject to redemption, shares issued	0	0
Redeemable convertible preferred stock, Series A - subject to redemption, shares outstanding	0	0
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	17,441,917	17,488,032
Common stock, shares outstanding	17,357,160	17,411,651
Treasury stock, shares	84,757	76,381

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Revenue	$ 2,340	$ 4,499	$ 4,053	$ 7,686
Operating expenses:
Research and development	5,701	10,533	12,504	26,537
Selling, general and administrative	6,089	8,774	14,267	18,002
Depreciation and amortization	996	1,422	2,686	2,965
Total operating expenses	12,786	20,729	29,457	47,504
Operating loss	(10,446)	(16,230)	(25,404)	(39,818)
Interest expense	4,488	1,872	8,774	3,556
Change in fair value of financial instruments	380	7,325	(881)	7,927
Other income, net	(5)	(4)	(15)	(14)
Net loss	(15,309)	(25,423)	(33,282)	(51,287)
Other comprehensive loss (income), net:
Foreign currency translation	523	(378)	289	438
Comprehensive loss	$ (15,832)	$ (25,045)	$ (33,571)	$ (51,725)
Net loss per share:
Basic and diluted net loss per share	$ (0.92)	$ (1.98)	$ (2)	$ (4.05)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - 6 months ended Dec. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]
Beginning balance at Jun. 30, 2016	$ (86,733)	$ 175	$ 398,862	$ (485,363)	$ 380	$ (787)
Beginning balance, shares at Jun. 30, 2016		17,488,032
Net loss	(33,282)			(33,282)
Foreign currency translation	(289)				(289)
Share-based compensation expense	2,244	$ (1)	2,245
Share-based compensation expense, shares		(37,739)
Shares forfeited in lieu of payroll taxes	(32)					(32)
Shares forfeited in lieu of payroll taxes, shares		(8,376)
Ending balance at Dec. 31, 2016	$ (118,092)	$ 174	$ 401,107	$ (518,645)	$ 91	$ (819)
Ending balance, shares at Dec. 31, 2016		17,441,917

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (33,282)	$ (51,287)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,686	2,965
Share-based compensation expense	2,244	7,020
Recognition of deferred revenue	(1,769)	(2,358)
Non-cash interest expense	8,342	1,194
Change in fair value of financial instruments	(881)	7,927
Non-cash sublease charge	709
Changes in assets and liabilities:
Restricted cash - related party		2,264
Accounts receivable	(2,540)	(797)
Inventories	(11)	29
Prepaid expenses and other current assets	387	(1,825)
Other assets		6
Accounts payable	7	6,651
Due to related party		(2,264)
Accrued expenses	(2,672)	1,255
Deferred revenue	3,503	15,501
Other long-term liabilities	4
Net cash used in operating activities	(23,273)	(13,719)
Cash flows from investing activities:
Purchases of property, plant and equipment	(482)	(6,750)
Net cash used in investing activities	(482)	(6,750)
Cash flows from financing activities:
Principal payments on long-term debt and capital lease obligations	(261)	(289)
Payment of royalty liability	(41)	(309)
Proceeds from former CEO loan		600
Proceeds from the issuance of long-term debt		10,000
Proceeds from the issuance of convertible debt, net of financing fee	15,000
Proceeds from the issuance of common stock, net of issuance costs		9,387
Proceeds from the issuance of preferred stock, net of issuance costs		7,172
Payment of financing costs		(143)
Shares forfeited in lieu of payroll taxes	(32)
Dividend payment on redeemable convertible preferred stock		(280)
Increase in restricted cash	(300)
Net cash provided by financing activities	14,366	26,138
Effect of exchange rate changes on cash	(4)	(1)
Net (decrease) increase in cash and cash equivalents	(9,393)	5,668
Cash and cash equivalents at beginning of period	18,702	12,303
Cash and cash equivalents at end of period	9,309	17,971
Supplemental disclosure of cash flow information
Cash paid for interest	432	2,059
Supplemental disclosure of non-cash activities
Purchases of property, plant and equipment in accounts payable and accrued expenses	7	$ 12,280
Non-cash principal payments on long-term debt	$ 2,263

Description of Business and Una

Description of Business and Unaudited Financial Statements	6 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Description of Business and Unaudited Financial Statements	1. Description of Business and Unaudited Financial Statements Unilife Corporation (together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Delaware in 2009 and is based in the Commonwealth of Pennsylvania. The Company began operations in Australia in 2002. The Company is a designer, manufacturer, and supplier of innovative injectable drug delivery systems that can enhance and differentiate the injectable products of our pharmaceutical and biotechnology customers. While the Company has a broad portfolio of proprietary product platforms, the Company has focused the business on the Company’s wearable injector products. The Company believes its products are differentiated from conventional products, with innovative features and functionality designed to optimize the safe, simple, and convenient administration of injectable therapies. The majority of the Company’s products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by end-users, such as patients or health-care providers. The Company customizes products within each of its platforms to address specific customer, therapy, patient and/or commercial requirements. The Company is focusing primarily on active and new customer programs in its portfolio of wearable injector products, which the Company expects will improve operating efficiencies and better position the Company to take advantage of commercial opportunities within the fast-growing market for wearable injectors. The Company’s wearable injector customers include Amgen Inc., MedImmune LLC (“MedImmune”), and Sanofi S.A. (“Sanofi”). In addition to the filling, assembly and/or packaging of the Company’s products with injectable therapies, the Company’s customers are also, with respect to most of its products, responsible for the regulatory approval, sale and marketing of their final drug-device combination products. While at this point the Company’s products have not been sold to end users with the Company’s customers’ injectable therapies, the Company can generate revenue from customization programs, upfront fees, licensing fees, device and development materials, and exclusivity fees. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited consolidated financial statements contain all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented as required by Rule 10-01 of Regulation S-X. Interim results may not be indicative of results for a full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended June 30, 2016, or fiscal 2016, contained in its Annual Report on Form 10-K.

Internal Investigation and List

Internal Investigation and Listed Exchange Update	6 Months Ended
	Dec. 31, 2016
Accounting Changes And Error Corrections [Abstract]
Internal Investigation and Listed Exchange Update	2. Internal Investigation and Listed Exchange Update On May 8, 2016, the Company announced an investigation into violations of the Company’s policies and procedures and possible violations of laws and regulations by the Company’s former Chief Executive Officer, Alan Shortall, whose employment with the Company ceased on March 11, 2016, and its former Chairman, Jim Bosnjak, who resigned from the Company’s Board of Directors (the “Board”) on August 24, 2015 (the “Investigation”). The Board established a Special Committee to oversee the Investigation. Independent counsel conducted the Investigation with the assistance of an advisory firm with forensic accounting expertise. The Investigation was completed on October 7, 2016 and did not identify any material financial loss. The filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 (the “March 2016 10-Q”) and the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the “2016 10-K”) were delayed as a result of the Investigation. On October 17, 2016, the Company received a notice from the Listing Qualifications department of NASDAQ stating that, because the Company did not maintain a minimum Market Value of Listed Securities (“MVLS”) of $50.0 million for the last 30 consecutive business days, the Company was no longer in compliance with NASDAQ Listing Rule 5450(b)(2)(A). The Company has been provided a period of 180 calendar days, or until April 17, 2017, to regain compliance with the minimum MVLS listing requirement. If at any time on or before April 17, 2017, the MVLS of the Company’s common stock, par value $0.01 per share (“common stock”), closes at $50.0 million or more for a minimum of 10 consecutive business days, NASDAQ will provide the Company with written confirmation that the Company has achieved compliance with the minimum MVLS listing requirement and the matter will be closed. In the event that the Company does not regain compliance with the minimum MVLS listing requirement on or before April 17, 2017, NASDAQ will provide the Company with written notification that its securities are subject to delisting. At that time, the Company would be permitted to appeal the delisting determination to a NASDAQ Hearings Panel or apply to transfer its common stock to The NASDAQ Capital Market (provided that it satisfied the requirement for continued listing on that market).

Liquidity

Liquidity	6 Months Ended
	Dec. 31, 2016
Text Block [Abstract]
Liquidity	3. Liquidity As of December 31, 2016, the Company’s cash and cash equivalents were $9.3 million, restricted cash was $2.7 million and the book value of the Company’s debt was $126.1 million. As of December 31, 2016, the Company also had a working capital deficit of $3.1 million. Under the Company’s debt facilities, the Company was required to have a cash and restricted cash balance of $5.4 million at December 31, 2016. The Company incurred recurring losses from operations as well as negative cash flows from operating activities during fiscal year 2016 and the six months ended December 31, 2016, and anticipates incurring additional losses and negative cash flows until such time that it can generate sufficient revenue from the sale, customization, or exclusive use and licensing of its proprietary injectable drug delivery systems to pharmaceutical and biotechnology customers. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has taken or intends to take the steps delineated below to address its cash requirements, the success of which is largely beyond the Company’s control. The Company expects to generate cash receipts from wearable injector customers during fiscal year 2017 and the Company continues to have business development discussions with current and prospective wearable injector customers. The Company does not expect these receipts to be sufficient to materially improve the Company’s liquidity position and is unable to predict the amount, if any, or the timing of such receipts or any proceeds from these business development discussions. The Company has also engaged a financial advisory firm to further assist with fundraising efforts. This process could result in any number of alternatives, which are likely to be highly dilutive to Company stockholders. There is no assurance that the Company will be successful in these efforts or, if successful, that the Company will be able to obtain favorable terms. In February 2016, the Company and Unilife Medical Solutions, Inc., a wholly owned subsidiary of the Company (“Unilife Medical Solutions”) and, together with the Company, (the “Company Parties”) entered into a Securities Purchase Agreement (the “Counterparty SPA”) with Amgen Inc. (the “Counterparty”), pursuant to which the Counterparty agreed to purchase from the Company Parties a new series of 6% Senior Secured Convertible Notes Due 2023 in the aggregate original principal amount of up to $55.0 million (the “Notes”). Pursuant to the Counterparty SPA, the Notes were to be issuable in up to three separate closings. The Company issued to Counterparty the first Note in the aggregate original principal amount of $30.0 million on February 22, 2016, and Counterparty paid to the Company $30.0 million in exchange therefor (“February 2016 Convertible Note”). Pursuant to the Counterparty SPA, the Counterparty originally was entitled to purchase two additional Notes in January 2017 (the “2017 Convertible Note”) and January 2018 (the “2018 Convertible Note”) in the amounts of $15.0 million and $10.0 million respectively. Each of On October 24, 2016, the Company Parties and the Counterparty entered into a letter agreement (the “October Counterparty Letter Agreement”), pursuant to which the Company Parties agreed to issue to the Counterparty on October 24, 2016, in accordance with the terms and conditions of the Counterparty SPA and the October Counterparty Letter Agreement, a portion of the 2017 Convertible Note (the “Accelerated Convertible Note”) in the initial principal amount of $10.0 million plus a $0.6 million financing fee (the “Financing Fee”), for an aggregate initial principal amount of $10.6 million. In consideration for issuing the Accelerated Convertible Note, the Counterparty paid to the Company $10.0 million on October 24, 2016. On December 20, 2016, the Company issued the remaining portion of the 2017 Convertible Note in the aggregate principal amount of $5.0 million (the “December 2016 Convertible Note”) and the Counterparty paid to the Company $5.0 million in exchange therefor. The terms of the December 2016 Convertible Note are substantially the same as those of the February 2016 Convertible Note and the Accelerated Convertible Note. In connection with the issuance of the December 2016 Convertible Note, the Lender (as defined below) consented to the issuance of the December 2016 Convertible Note and the Company agreed to obtain the Lender’s written consent prior to closing on a transaction to sell Company securities to a third party other than the Counterparty or any employee of the Company or Unilife Medical Solutions during the four-month period commencing January 1, 2017 and ending April 30, 2017. The 2018 Convertible Note will continue to be issuable in January 2018 by the Company Parties to the Counterparty in accordance with the terms and conditions of the Counterparty SPA. There can be no assurance as to when or if the Counterparty will purchase all or any part of the 2018 Convertible Note . As previously announced, the Company has focused the business primarily on active and new customer programs in its portfolio of wearable injector systems. In connection with this new focus, the Company has been evaluating the prospects of its non-wearable injector customer programs and attempting to negotiate terminations of certain non-wearable injector customer contracts. The Company has separate contracts with one customer for its prefilled syringes and wearable injectors. In connection with the prefilled syringe contract with such customer, the Company previously received $10.0 million which may be refundable to the customer, including for termination for certain events and is therefore recorded in long-term deferred revenue. Although this $10.0 million is not yet refundable, the Company and the customer are amicably negotiating the potential termination of the contract and the potential repayment to the customer of all or a portion of the $10.0 million potentially through a long-term financial instrument. The outcome of these negotiations is still uncertain. The Company’s ability to raise capital is limited and there can be no assurance that financing will be available when needed. The Company will not be able to obtain financing through offerings of its securities registered under the Securities Act of 1933, as amended (the “Securities Act”), until the Company can prepare, file with the SEC, and cause to become effective a registration statement on Form S-1. We are not currently eligible to register the offer and sale of our securities using a registration statement on Form S-3, cannot use our existing Form S-3 and will not become eligible to use Form S-3 until we have timely filed certain periodic reports required under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for 12 consecutive calendar months. The Company believes its existing cash at December 31, 2016 will provide the Company with sufficient liquidity to fund the Company’s operations into March 2017 without falling below its minimum cash balance requirement under the Company’s debt facilities of $5.1 million. The Company believes that any potential proceeds from fundraising efforts, the potential issuance of the 2018 Convertible Note, potential customer cash receipts, and potential proceeds from business development discussions will provide the Company with enough liquidity to fund its operations for the next twelve months. However, there can be no assurance that any cash from fundraising efforts, if successful, the potential issuance of the 2018 Convertible Note, potential customer cash receipts, and potential proceeds from business development discussions will be available when needed, as such sources of liquidity largely are beyond the Company’s control. If we are unable to obtain financing when needed, we may be in default under one or more of our debt obligations unless we are able to obtain waivers from our lenders. A breach of any of the covenants related to our debt instruments could result in a higher rate of interest to be paid or the lenders could elect to declare all amounts outstanding under the applicable agreements to be immediately due and payable. If the lenders were to make such a demand for repayment, we would be unable to pay the obligations as we do not have existing facilities or sufficient cash on hand to satisfy these obligations. Under the circumstances, we also would be unable to pay our other obligations as they come due, which could prompt our creditors to pursue other remedies. These factors continue to raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation, derivative liability valuation, warrant liability valuation, preferred stock conversion liability (the “Preferred Stock Conversion”) valuation, share-based compensation expense, restructuring obligations, contingencies, recoverability of goodwill, long-lived assets and useful lives of property, plant and equipment. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Property, Plant and Equipment Property, plant and equipment, including significant improvements, are recorded at cost, net of accumulated depreciation and amortization. Repairs and maintenance are expensed as incurred. Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease Interest cost incurred in connection with the development and construction of significant new machinery and equipment, as well as facility related costs have been capitalized as one of the elements of cost and are being amortized over the asset’s respective useful life. The Company evaluates the recoverability of the recorded value of long-lived assets periodically to determine if facts and circumstances exist that would indicate that the assets might be impaired or that the useful lives should be modified. As part of this valuation, the Company develops projections of undiscounted future cash flows of the asset or asset group. The projections of undiscounted cash flows include a combination of revenue from customization and development activities, capital expenses that may be necessary to support projected product sales and commercial product sales. As customization and development activities are completed, commercial product sales are expected to scale-up. Expectations of future commercial product sales included in the projections used for the impairment analysis are based on customer-specific information as well as market estimates relating to the anticipated drugs and therapies being targeted for use with the Company’s products. These projections also include assumptions of future sales growth and profitability based on contracts entered into with customers as well as future contracts to be entered into based on the current discussions and negotiations with existing and prospective customers. Sales projections are based on assumptions including a transition in the market toward patient self-administration of injectable therapies as well as transitions in the market toward biological-based drugs in the pharmaceutical industry development pipeline. The Company’s future sales could also be impacted by factors such as its ability to obtain new and retain existing customers, the timing and extent of the customers’ drug development activities as well as the regulatory approval process, drug efficacy and industry acceptance of injectable therapies. If the Company’s future sales or its projections of future sales are impacted by any one or more of the preceding factors, it will reassess the recorded value of the long-lived assets. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value. In connection with the Company’s focus on wearable injector products, the Company evaluated the prospects of its non-wearable injector customer and supplier programs in fiscal year 2016. As a result of negotiations related to those supplier and customer programs and the Company’s evaluation of those programs and potential disposition of certain assets, the Company determined that certain of its long lived-assets were impaired and the Company incurred a $26.6 million non-cash asset impairment charge primarily related to machinery and equipment and construction in process in the third quarter of fiscal 2016. There were no asset impairment charges for the three and six months ended December 31, 2016 and 2015. Goodwill and Intangible Assets Goodwill is the excess of purchase price over the fair value of net assets acquired in business acquisitions. Goodwill is subject to, at a minimum, an annual impairment assessment of its carrying value at the reporting unit level. Additional impairment assessments would be performed if events and circumstances warranted such additional assessments during the year. The Company has one reporting unit which includes its product lines, the base technology which it obtained as part of its November 2002 acquisition of Unitract Syringe Pty Limited, and the manufacturing capability which it obtained in its January 2007 acquisition of Integrated BioSciences, Inc. As required under GAAP, the Company is required to evaluate goodwill for impairment at least annually and more frequently if certain trigger events occur. The Company determined that the continuing losses incurred by the Company and its negative equity, and the decline in the Company’s stock price constituted trigger events that occurred in the six months ended December 31, 2016 requiring an evaluation of the carrying value of the Company’s goodwill. Potential impairment of goodwill is identified by comparing the fair value with its carrying value. The Company performed a goodwill valuation during the interim period as of September 30, 2016 using a combination of the market approach and a discounted cash flow method under the income approach. The Company determined an overall business enterprise value (determined by the fair of equity plus the fair value of debt) by taking a weighted average from the results of the discounted cash flow under the income approach (40%) and the market approach based on the Company’s market capitalization (60%). Under the income approach, the Company calculates the fair value of its reporting unit based on the present value of estimated future cash flows. Management judgment is necessary to evaluate the impact of operating and external market changes and to estimate the future cash flows used to measure fair value. The Company’s estimate of cash flows considers past performance, current and anticipated market conditions, and internal projections and operating plans which incorporate estimates for sales growth, profitability and capital spending. Additional assumptions include forecasted growth rates and estimated discount rates which are risk adjusted for current market conditions. The Company believes such assumptions reflect current and anticipated market conditions and are consistent with those that would be used by other marketplace participants for similar purposes but are subject to change due to changing conditions. The weighting of the results of each method to assess the overall business enterprise value was considered reasonable as greater weight was given to the market capitalization based on the quoted stock price as this is considered more reliable information as it is publicly available and not subject to management judgment or estimate, whereas, discounted cash flow under the income approach is subject to management estimates and judgments. Although based on the results of the business enterprise value calculation there was no indication of impairment of goodwill, the Company determined as a result of the continuing losses incurred by the Company and its negative equity, and other indicators of impairment and the decline in the Company’s stock price, that an additional step 2 analysis was warranted under generally accepted accounting principles. The Company performed a Step 2 valuation of goodwill by valuing certain intangible assets (primarily patents, trademarks and tradenames). The Company considered the impact of all assets and liabilities in allocating the fair value of the Company to determine the fair value of goodwill and whether any impairment is indicated. The Company believes these intangible assets would generate the most significant difference between implied fair value and book value as part of completing a Step 2 purchase price allocation for the purpose of determining the value of goodwill for impairment. The valuation of intangible assets was performed using the relief from royalty method under the income approach. This method utilizes the Company’s revenue projections and assigns values based on determination of appropriate royalty rates considering relevant industry information. The Company then utilized the fair value of its intangible assets along with the estimated fair value of its other assets and liabilities to determine the implied goodwill compared to the carrying value of goodwill. The residual fair value based on the results of the Step 2 valuation indicated there was no impairment of goodwill. The Company performed a qualitative review through December 31, 2016 and no events occurred or circumstances changed that would more likely than not reduce the fair value of the goodwill below its carrying value. The Company considered that the results of the valuation of goodwill indicated there was no impairment of goodwill and also indicated significant cushion between the implied fair value of goodwill and its carrying value and, therefore, the Company has concluded that no goodwill impairment existed as of December 31, 2016. Definite-lived intangible assets include patents which are amortized on a straight-line method over their estimated useful lives of 15 years and are included in other assets. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate a possible impairment, if the sum of the estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset is less than the carrying amount of the asset, an impairment may be recognized. Measurement of an impairment loss is based on the excess of the carrying value of the asset over its fair value. Definite-lived intangible assets were less than $0.1 million as of December 31, 2016 and June 30, 2016 and are recorded in other assets on the consolidated balance sheet. There were no impairments recorded on intangible assets during the three and six months ended December 31, 2016 and 2015. Share-Based Compensation The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility. Revenue Recognition The Company recognizes revenue from industrialization and development fees, licensing fees and product sales. The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. The Company recognizes license revenue over the life of the patents of the products relating to the license. Revenue from industrialization and development fees is recognized as services are rendered, under the completed contract method, under the proportional performance method or upon achievement of the “at risk” substantive milestone events, which represent the culmination of the earnings process related to such events. Substantive milestones can include specific deliverables such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made as services are rendered or when substantive milestones are achieved. The Company considers whether a milestone is substantive at the inception of the agreement. The consideration earned from the achievement of a milestone must meet all of the following criteria to be considered substantive: • It is commensurate with either of the Company’s performance to achieve the milestone, or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; • It relates solely to past performance; and • It is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the substantive milestone. Fees for completed, substantive milestones, which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance or the termination of refund rights. Fair Value Measurements In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs. The carrying value of financial instruments such as accounts receivable, accounts payable and accrued expenses are reasonable estimates of their fair value because of the short maturity of these items. The Company believes that the current carrying amount of its long-term debt approximates fair value because the terms on these instruments are similar to those terms that the Company would currently be able to receive for similar instruments of comparable maturity. The Company has elected to measure its royalty agreement liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions that the Company believes would be made by a market participant. In particular, the valuation analysis uses a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty agreement liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream. The Company accounts for derivative financial instruments in accordance with ASC 815, Derivative and Hedging — Contracts in Entity’s Own Equity. Instruments which do not have fixed settlement provisions are deemed to be derivative instruments and are valued based on an average of a Monte Carlo and lattice model. The Preferred Stock Conversion valuation analysis used the estimated dividend rate based on the volume-weighted average price of the Company’s common stock at the date the Preferred Stock Conversion is measured. The warrant liability is valued using a Black-Scholes option-pricing model. Interest Expense The Company recognizes interest expense in the consolidated statements of operations and comprehensive loss for all debt instruments using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating the interest expense over the relevant period. The effective interest rate is the rate that exactly discounts the estimated future cash payments through the expected life of the financial instrument to the net carrying amount of the financial liability. The application of the method has the effect of recognizing expense payable on the instrument evenly in proportion to the amount outstanding over the period to maturity or repayment. In calculating the effective interest rate, the Company estimates cash flows considering all contractual terms of the financial instrument, including fees for early redemption and all other premiums and discounts. New Accounting Pronouncements Effective During the Period In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12 “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved After the Requisite Service Period” which is part of ASC 718: Compensation-Stock Compensation. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and not be reflected in the estimate of the grant-date fair value of the award. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The guidance became effective July 1, 2016 and the Company elected to apply the guidance prospectively for all awards granted or modified after the effective date. The adoption of the new guidance did not have a material impact on the Company’s financial condition, results of operations or cash flows. New Accounting Pronouncements Not Yet Adopted In May 2014, FASB issued ASU 2014-09 “Revenue from Contracts with Customers” and amended by ASU 2016-08 “Principle versus Agent Considerations”, ASU 2016-10 “Identifying Performance Obligations and Licensing”, and ASU 2016-12 “Narrow-Scope Improvements and Practical Expedients”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers” which deferred the effective date of ASU 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Early application is permitted only as of annual periods beginning after December 15, 2016, including interim reporting periods within that reporting period. With the deferral, the new standard is effective for the Company, on July 1, 2018, with early adoption permitted one year prior. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has reviewed the new standards and has begun to consider the impact of the standard on its ongoing financial reporting, but has not yet made any conclusions. In August 2014, FASB issued ASU 2014-15 “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The guidance requires an entity to perform a going concern assessment by evaluating its ability to meet its obligations for a look-forward period of one year from the financial statement issuance date. Disclosures are required if it is probable an entity will be unable to meet its obligations within the look-forward period. Incremental substantial doubt disclosure is required if the probability is not mitigated by management’s plans. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, results of operations and cash flows. In November 2015, the FASB issued new guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the new guidance. The new guidance is effective for the Company on July 1, 2017, with early adoption permitted as of the beginning of an interim or annual reporting period. The new guidance may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company is evaluating the impact that the new guidance will have on its consolidated financial statements and related disclosures; however, at the present time the Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred. In January 2016, the FASB issued new guidance related to the recognition and measurement of financial assets and liabilities. The new guidance makes targeted improvements to GAAP impacting equity investments (other than those accounted for under the equity method or consolidated), financial liabilities accounted for under the fair value election, and presentation and disclosure requirements for financial instruments, among other changes. The new guidance is effective for the Company on July 1, 2018, with early adoption prohibited other than for certain provisions. The Company is evaluating the impact that the new guidance will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. The principal change under the new accounting guidance is that lessees under leases classified as operating leases will recognize a right-of-use asset and a corresponding lease liability. Current lease accounting does not require lessees to recognize assets and liabilities arising under operating leases on the balance sheet. Under the new guidance, lessees (including lessees under leases classified as finance leases and operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Expense recognition and cash flow presentation guidance will be based upon whether the lease is classified as an operating lease or a finance lease (the classification criteria for distinguishing between finance leases and operating leases is substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current guidance). The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company has reviewed the new standard, has begun to identify its contracts that might be impacted by the standard, and has begun to consider the impact of the standard on its ongoing financial reporting, but has not yet made any conclusions. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including guidance relating to accounting for income taxes with respect to share-based payment awards; providing generally that excess tax benefits related to share-based awards should be recorded as a reduction to income tax expense (currently, excess tax benefits generally are recorded to additional-paid-in-capital); providing generally that excess tax benefits related to share-based awards should be classified along with other income tax cash flows as an operating activity (currently, excess tax benefits generally are separated from other income tax cash flows and classified as a financing activity); providing that an entity may make an accounting policy election either to base compensation cost accruals on the number of awards expected to vest (as required by current guidance) or to account for forfeitures when they occur; modifying the current exception to liability classification such that partial cash settlement of an award for tax withholding purposes would not result, by itself, in liability classification of the award if the amount withheld does not exceed the maximum statutory tax rate in the employees' applicable jurisdictions (currently, an award cannot qualify for equity classification, rather than liability classification, if the amount withheld exceeds the minimum statutory withholding requirements); and providing that cash paid by an employer when directly withholding shares for tax withholding purposes should be classified as a financing activity on the statement of cash flows (currently there is no authoritative guidance addressing this classification issue). The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted (if early adoption occurs in an interim period, any adjustments will be reflected as of the beginning of the fiscal year that includes the interim period). Depending on the particular issue addressed by the guidance, application of the guidance will be made prospectively, retrospectively or subject to a retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on the Company's results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows, Clarification of Certain Cash Receipts and Cash Payments”, which provides guidance on the presentation and classification of eight specific cash flow issues. Those issues are cash payment for debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instrument or other debt instrument with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; cash received from settlement of corporate-owned life insurance policies; distribution received from equity method investees; beneficial interest in securitization transactions; and classification of cash receipts and payments that have aspect of more than one class of cash flows. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017 with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash”. The amendments in this Update require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The amendments in this Update should be applied using a retrospective transition method to each period presented. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure and cash flows, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, and results of operations. In January 2017, the FASB issued ASU No. 2017-04 “Simplifying the Test for Goodwill Impairment”. The amendments in this Update modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. To simplify the subsequent measurement of goodwill, the FASB eliminated Step 2 from the goodwill impairment test. Under the amendments in this Update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. For public entities, the amendments in this Update are effective on a prospective basis for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. Upon adoption, the Company will be required to disclose the nature of and reason for the change in accounting principle upon transition and that disclosure should be provided in the first annual period and in the interim period within the first annual period when the entity initially adopts the amendments. The Company is currently evaluating the impact of these amendments; however, the adoption of this guidance is not expected to have any impact on the Company’s financial condition

Equity Transactions and Share-B

Equity Transactions and Share-Based Compensation	6 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Transactions and Share-Based Compensation	5. Equity Transactions and Share-Based Compensation The Company recognized share-based compensation expense related to equity awards to employees, directors, consultants and service providers of $1.2 million and $3.4 million during the three months ended December 31, 2016 and 2015, respectively, and $2.2 million and $7.0 million during the six months ended December 31, 2016 and 2015, respectively. On July 29, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (the “New Sales Agreement”) with Cantor Fitzgerald & Co., pursuant to which the Company may, from time to time, issue and sell shares of common stock, having an aggregate offering price of up to $25.0 million. The Company issued 380,011 shares for net proceeds of $4.6 million under the New Sales Agreement during the six months ended December 31, 2015. The Company used the proceeds for working capital needs and other general corporate purposes. The Company did not utilize this facility during the six months ended December 31, 2016. On July 29, 2015, the Company entered into an equity purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company may sell, from time to time, to LPC up to $45.0 million in shares of the Company’s common stock through July 2017, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company issued 324,465 shares of common stock to LPC and received net proceeds of $4.8 million under the LPC Purchase Agreement during the six months ended December 31, 2015. The Company used the proceeds for working capital needs and other general corporate purposes. The Company did not utilize this facility during the six months ended December 31, 2016. We are not currently eligible to register the offer and sale of our securities using a registration statement on Form S-3, cannot use our existing Form S-3 and will not become eligible to use Form S-3 until we have timely filed certain periodic reports required under the Exchange Act for 12 consecutive calendar months. As a result, the Company will not be able to obtain financing under the New Sales Agreement or LPC Purchase Agreement at least until the Company is eligible to register the offer and sale of our securities using a registration statement on Form S-3. Stock Options and Warrants The Company has granted stock options to certain employees and directors under the Employee Share Option Plan (the “Plan”). The Plan is designed to assist in the motivation and retention of employees and directors and to recognize the importance of employees and directors to the long-term performance and success of the Company. The Company has also granted stock options to certain service providers outside of the Plan. The majority of the options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to three years. Share-based compensation expense related to options granted to employees and directors is recognized on a straight-line method over the related vesting term. Share-based compensation expense related to options granted to service providers is recognized ratably over each vesting tranche of the options. In December 2016, the Company amended its Amended and Restated 2009 Stock Incentive Plan or “Amended Stock Plan” to increase the number of shares of common stock available for issuance under the Amended Stock Plan by approximately 2.4 million shares. In January 2017, the Company granted 1,100,000 stock options and 791,173 restricted stock units at fair market value to its employees. Under the terms of the LPC Purchase Agreement, the Company was required to obtain the consent of LPC prior to completing the Preferred Stock Purchase Agreement. The Company obtained such consent on November 9, 2015 and contemporaneously issued a five-year warrant to purchase 90,000 shares of common stock to LPC at an exercise price of $10.00 per share. The Company performed a Black-Scholes valuation on the warrant and valued the warrant at $5.40 per share of common stock. Accordingly, the Company recorded $0.5 million during the three months ended December 31, 2015 associated with the issuance of the warrant as a component of redeemable convertible preferred stock issuance cost. LPC has not exercised any warrants as of December 31, 2016. On December 31, 2016, t On February 22, 2016, in connection with entering into the Eighth Amendment to the Credit Agreement (as defined below) and the Sixth Amendment to the Royalty Agreement (as defined below), the Company issued to ROS (as defined below) warrants to purchase 1,673,981 shares of common stock, with an exercise price of $12.50 per share, subject to adjustment for certain events, which may be exercised at any time and from time to time until February 22, 2026. ROS has not exercised any warrants as of December 31, 2016. Upon issuance, t he Company performed a Black-Scholes valuation on the warrant and valued the warrant at $7.20 per share of common stock. Accordingly, the Company recorded a $12.1 million warrant liability during the three months ended March 31, 2016 associated with the issuance of the warrant. On December 31, 2016, t he Company performed a Black-Scholes valuation on the warrant liability to revalue the warrant and valued the warrant at $1.24 per share of common stock. The warrant liability was revalued to $2.1 million at December 31, 2016. The following is a summary of activity related to stock options held by employees and directors during the six months ended December 31, 2016: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of July 1, 2016 102,552 $ 40.10 Cancelled (8,686 ) 49.25 Outstanding as of December 31, 2016 93,866 39.25 5.5 $ 0 Exercisable as of December 31, 2016 78,366 $ 39.79 5.3 $ 0 The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the six months ended December 31, 2016: Number of Options & Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of July 1, 2016 1,793,981 $ 12.68 Granted — — Expired — — Outstanding as of December 31, 2016 1,793,981 $ 12.68 8.8 $ — Exercisable as of December 31, 2016 1,793,981 $ 12.68 8.8 $ — The aggregate intrinsic value is defined as the difference between the market value of the Company’s common stock as of the end of the period and the exercise price of the in-the-money stock options. There were no options exercised during the six months ended December 31, 2016 and 2015, respectively. There were no options granted during the three and six months ended December 31, 2016 and 2015, respectively. Restricted Stock Awards and Units The Company has granted shares of restricted stock to certain employees, directors and consultants under the Amended and Restated 2009 Stock Incentive Plan. During the period prior to vesting, the holder of the non-vested restricted stock will have the right to vote and the right to receive all dividends and other distributions declared. All non-vested shares of restricted stock are reflected as outstanding; however, they have been excluded from the calculation of basic earnings per share. For employees, the fair value of restricted stock is measured on the date of grant using the price of the Company’s common stock on that date. Share-based compensation expense for restricted stock issued to employees is recognized on a straight-line basis over the requisite service period, which is generally the longest vesting period. For restricted stock granted to consultants, the fair value of the awards will be re-valued on a quarterly basis and marked to market until vested. Share-based compensation expense for restricted stock issued to consultants is recognized ratably over each vesting tranche. The following is a summary of activity related to awards of restricted stock and restricted stock units during the six months ended December 31, 2016: Number of Restricted Stock Awards and Units Weighted Average Grant Date Fair Value Unvested as of July 1, 2016 882,948 $ 15.41 Granted 313 2.78 Vested (103,087 ) 29.33 Cancelled (94,159 ) 7.33 Unvested as of December 31, 2016 686,015 $ 14.42 Preferred Stock Purchase Agreement On November 9, 2015, the Company entered into and closed a Preferred Stock Purchase Agreement (the “Preferred Stock Purchase Agreement”) with a fund (the “Fund”). Pursuant to the Preferred Stock Purchase Agreement, the Company issued and sold to the Fund 790 shares of the Company’s newly designated Series A Redeemable Convertible Preferred Stock of the Company, par value $0.01 per share (the “Series A Preferred Stock”), at a 5% original issue discount and at a purchase price of $10,000 per share for total gross proceeds to the Company of $7.5 million. Prior to the full conversion of the Series A Preferred stock (as more fully discussed below), the Series A Preferred Stock was convertible into shares of common stock at a fixed conversion price of $10.00 per share (the “Conversion Price”). The shares of Series A Preferred Stock were offered and sold in a registered direct offering (the “Offering”) pursuant to the Company’s shelf registration statement (File No. 333-197122), which was declared effective by the SEC on October 3, 2014. From the date of issuance, each share of Series A Preferred Stock accrued dividends at a rate of 8.0% per annum (the “Dividend Rate”), subject to adjustment as discussed below, on its face value of $10,000 (the “Face Value”), payable upon conversion or redemption of such share and when, as and if otherwise declared by the Board. Dividends were paid either in cash or in shares of common stock at the Company’s sole discretion and were valued at (i) if there was no Trigger Event (as defined below), (A) 95.0% of the average of the 5 lowest individual daily volume weighted average prices of the common stock on the Trading Market during the applicable Measurement Period, which may be non-consecutive, less $0.50 per share of common stock, not to exceed (B) 100% of the lowest sales price on the last day of such Measurement Period less $0.50 per share of common stock or (ii) following any Trigger Event, (A) 80.0% of the lowest daily volume weighted average price during any Measurement Period for any conversion by Holder, less $1.00 per share of common stock, not to exceed (B) 80.0% of the lowest sales price on the last day of any Measurement Period, less $1.00 per share of common stock. “Trigger Event” is defined as including, among other events, our breach of the Certificate of Designations and any transaction documents, the occurrence of certain defaults under our material agreements, the suspension of our NASDAQ listing, bankruptcy, the appointment of a receiver, our failure to timely file any report under the Exchange Act or the unenforceability of any material provision of the Certificate of Designations. “Trading Market” is defined as the principal trading exchange or market for the common stock. “Measurement Period” is defined as the period beginning on the date of issuance of any such shares of Series A Preferred Stock and ending, if no Trigger Event has occurred 3 trading days, and if a Trigger Event has occurred 30 trading days, after the number of shares have been delivered with respect to a conversion notice. The Dividend Rate was adjusted (i) downward by an amount equal to 100 basis points for each amount, if any, equal to $0.50 per share of common stock that the volume weighted average price of our common stock on any trading day rose above $15.00, down to a minimum of 0.0%; and (ii) upward by an amount equal to 150 basis points for each amount, if any, equal to $0.50 per share of common stock that volume weighted average price of our common stock on any trading day fell below $7.00, up to a maximum of 15.0%. In addition, the Dividend Rate was adjusted upward by 10.0% upon any Trigger Event. Each share of Series A Preferred Stock was convertible into such number of shares of common stock equal to the Face Value divided by the Conversion Price. Upon any conversion, the Company issued common stock at the Conversion Price and paid the dividend and conversion premium (“Dividend”) (in one instance in cash and the remaining instances in stock at the Company’s discretion). The Company was prohibited from issuing shares of common stock upon conversion of the Series A Preferred Stock if, as a result of the conversion, the holder, together with its affiliates, would beneficially own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, subject to adjustment up to 9.99% upon 61 days’ notice from the investor, which is referred to herein as the “Beneficial Ownership Limitation”. The Preferred Stock Purchase Agreement also contains representations, warranties and covenants customary for transactions of this type. In November 2015 and December 2015, the Fund delivered to the Company notices of conversion totaling an aggregate of 300 shares of Series A Preferred Stock (the “Initial Conversion Notices”) and the Company issued an aggregate of 1,025,499 shares of common stock and paid $0.3 million in cash to satisfy the Initial Conversion Notices. Calculations in the Initial Conversion Notices were based upon the occurrence of a Trigger Event. As described above, the amount of any Dividend varied based on the Company’s share price during the applicable Measurement Period. If the Company’s share price declined during the Measurement Period with respect to a conversion notice, the number of shares owed to the Fund pursuant to such conversion notice would have changed and the Company was then required to issue the additional shares owed. During December 2015, the Company issued an additional 518,784 shares of common stock as additional Dividend with respect to the Conversion Notices as a result of a decline in the share price during the applicable Measurement Periods. On January 4, 2016, the Fund delivered to the Company a notice of conversion for 40 shares of Series A Preferred Stock (the “January 4 th On February 3, 2016, Company entered into the First Amendment to the Preferred Stock Purchase Agreement with the Fund. Pursuant to the First Amendment to the Preferred Stock Purchase Agreement, the Company acknowledged that the Fund had at all times fully and completely complied with all of its obligations under the Preferred Stock Purchase Agreement. The Fund has converted all of the Preferred Shares, and the parties entered into the First Amendment to the Preferred Stock Purchase Agreement to resolve the final and total of number shares of common stock to be delivered by the Company to the Fund as a result of the conversion. Pursuant to the First Amendment to the Purchase Agreement, in full accord and satisfaction of all obligations under the Purchase Agreement and the remaining transaction documents (as defined in the Preferred Stock Purchase Agreement), the Company agreed to issue to the Fund an additional 831,668 shares (collectively, the “Shares”) of common stock, the approximate amount that may be issued under Nasdaq Listing Rule 5635(d) without shareholder approval which the Company did not obtain. On February 3, 2016, the Company issued and delivered to the Fund 725,000 of the Shares. On February 11, 2016, the Company issued and delivered to the Fund the remaining 106,668 Shares. Pursuant to the First Amendment to the Purchase Agreement, the Company has no further obligations to the Fund with respect to any of the Series A Preferred Stock, Conversion Notices (as defined in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series A Preferred Stock) or any of the transaction documents. The Company issued 2,784,693 shares of common stock to the Fund in connection with the Preferred Stock Purchase Agreement, as amended by the First Amendment to the Preferred Stock Purchase Agreement. The Fund is no longer the holder of any Series A Preferred Stock. The First Amendment to the Preferred Stock Purchase Agreement contained a mutual release of claims between the Company and the Fund and contained customary representations and warranties made by such parties. The Company also agreed to provide the Fund with indemnification for breaches of the First Amendment to the Preferred Stock Purchase Agreement and for certain third-party claims, and the Fund agreed to continue the same activity restrictions provided for in the Preferred Stock Purchase Agreement. The Company accounted for the Series A Preferred Stock and the related Dividend as two separate units, i.e. Series A Preferred Stock and Preferred Stock Conversion. The Company determined that the Series A Preferred Stock should be classified as temporary equity based on the requirement to provide registered shares of the Company’s common stock upon conversion and the related Dividend should be classified as a liability at fair value. Accordingly, the proceeds recorded as temporary equity for the Series A Preferred Stock represented the proceeds from the issuance less initial fair value of Preferred Stock Conversion and related issuance costs. As a result, on November 9, 2015, the Company recorded the net proceeds of $7.2 million between the Series A Preferred Stock ($2.8 million) and the initial Preferred Stock Conversion at its fair value ($4.4 million). After accounting for all Conversion Notices and First Amendment to the Preferred Stock Purchase Agreement, the Redeemable Convertible Preferred Stock, Series A, was reclassed from temporary equity to permanent equity and was valued at $0.0 million at March 31, 2016 and no further accounting was needed. The Preferred Stock Conversion was remeasured quarterly, and at March 31, 2016, the Preferred Stock Conversion was valued at $0.0 and no further accounting was needed .

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	6. Property, Plant and Equipment Property, plant and equipment consist of the following: December 31, 2016 June 30, 2016 (in thousands) Building $ 32,362 $ 32,362 Machinery and equipment 20,090 19,537 Computer software 2,986 2,986 Furniture and fixtures 792 1,386 Construction in progress 13,385 13,870 Land 2,036 2,036 Leasehold improvements 349 437 72,000 72,614 Less: accumulated depreciation and amortization (19,691 ) (17,841 ) Property, plant and equipment, net $ 52,309 $ 54,773 Under ASC 360 Property, Plant, and Equipment , the Company is required to evaluate the recoverability of the carrying amount of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In February 2016, the Company completed its review of strategic alternatives and announced the formation of a strategic collaboration centered upon the use of the Company’s portfolio of prefilled, customizable wearable injectors. In connection with this focus, the Company has been evaluating the prospects of its non-wearable injector customer and supplier programs. As a result of negotiations related to those supplier and customer programs and the Company’s evaluation of those programs and potential disposition of certain assets, the Company determined that certain of its long lived-assets were impaired during the third quarter of fiscal year 2016 and an impairment charge was recorded during that period. There were no impairment charges incurred for the three and six months ended December 31, 2016 and 2015. Construction in progress as of December 31, 2016 consisted of amounts incurred in connection with machinery and equipment and facility related costs, including capitalized interest. Interest capitalized during the three and six months ended December 31, 2016 and 2015 was $0.0 million and $0.7 million; and $0.0 million and $1.4 million respectively. Depreciation on property, plant and equipment during the three and six months ended December 31, 2016 and 2015 was $1.0 million and $2.7 million; and $1.4 million and $3.0 million, respectively. In December 2016, the Company announced that it had listed its York, Pennsylvania facility for sale due to unused capacity as a result of the Company’s focusing on its wearable injector products. Under ASC 360 Property, Plant, and Equipment

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	7. Goodwill The changes in the carrying amount of goodwill during the six months ended December 31, 2016 are as follows: (in thousands) Balance as of July 1, 2016 $ 9,423 Foreign currency translation (287 ) Balance as of December 31, 2016 $ 9,136

Accrued Expenses

Accrued Expenses	6 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Accrued Expenses	8. Accrued Expenses Accrued expenses consist of the following: December 31, 2016 June 30, 2016 (In thousands) Accrued payroll and other employee related expenses $ 3,109 $ 2,755 Accrued cost related to equipment 1,320 2,623 Accrued transaction costs 4,000 5,000 Accrued professional fees 964 2,010 Accrued other 6,501 1,322 Total accrued expenses $ 15,894 $ 13,710 Accrued transaction costs relate to the Company’s review of strategic alternatives incurred in fiscal 2016. Accrued other includes the $5.0 million liability related to the settlement of the two putative class actions and the derivative complaints. See note 11 “Contingencies” for additional discussion related to these matters.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt Long-term debt consists of the following: December 31, 2016 June 30, 2016 (In thousands) 10.25% Term loan, due March 2020 $ 64,303 $ 57,227 Royalty agreement liability 5,464 5,120 6.00% Senior secured convertible note, due February 2023 43,428 29,066 6.00% Mortgage loan, due December 2031 12,139 12,370 5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021 1,948 1,977 127,282 105,760 Less: unamortized debt discounts and issuance costs (1,177 ) (646 ) 126,105 105,114 Less: current portion of long-term debt (702 ) (669 ) Total long-term debt $ 125,403 $ 104,445 Term Loan On March 12, 2014, Unilife Medical Solutions entered into a Credit Agreement with ROS Acquisition Offshore LP (the “Lender”), an affiliate of OrbiMed Advisors (“OrbiMed”) (the “Credit Agreement,” and, as amended the “Amended Credit Agreement” or the “OrbiMed Financing”). Pursuant to and subject to the terms of the Amended Credit Agreement, the Company has fully utilized the capacity and borrowed principal amounts totaling $70.0 million (the “Loans”). Under the Amended Credit Agreement, Unilife Medical Solutions is required to maintain a minimum cash balance of $3.0 million and comply with certain other customary covenants. The Loans bear interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%. Lender agreed to defer all obligations of Unilife Medical Solutions to pay interest to the Lender for the period from January 1, 2016 through February 22, 2018 at the rate specified in the Amended Credit Agreement, which interest will be added to the outstanding principal amount of the Loans on the last day of each interest period. A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0% shall apply during the existence of a default under the Amended Credit Agreement. The Loans are interest-only until March 12, 2020. Unless the loan facility is otherwise terminated earlier pursuant to the terms of the Amended Credit Agreement, Unilife Medical Solutions is required to repay in full the unpaid principal amount of the Loans drawn down, together with all accrued and unpaid interest thereon plus a 10.0% repayment premium on March 12, 2020. Unilife Medical Solutions can make voluntary repayments at any time of any unpaid principal amount of the Loans, plus a 10.0% repayment premium. Unilife Medical Solutions must make mandatory prepayments in certain prescribed circumstances, including, without limitation, certain dispositions of assets and certain casualty events. In such events, Unilife Medical Solutions must prepay to Lender 100% of the net cash proceeds received. The obligations of Unilife Medical Solutions under the Amended Credit Agreement are guaranteed by the Company and each of its subsidiaries and the Amended Credit Agreement is secured by the assets of the Company and its subsidiaries. The security interests granted by Unilife Medical Solutions, the Company, Unilife Cross Farm LLC (“Cross Farm”), Unilife Medical Solutions Limited (“UMSL”) and Unitract Syringe Pty Limited (“Unitract Syringe”) are evidenced by, among other things, the Pledge and Security Agreement, dated as of March 14, 2014, by Unilife Medical Solutions, the Company, Cross Farm, UMSL, and Unitract Syringe in favor of Lender, for itself and as agent for Royalty Opportunities S.A.R.L. (“ROS”), the Mortgage and Security Agreement, dated March 12, 2014, by and between Cross Farm and Lender, for itself and as agent of ROS, and the General Security Deed, dated as of March 12, 2014, by Unitract Syringe, UMSL, and the Company in favor of the Lender, for itself and as agent of ROS. In connection with entering into the Eighth Amendment to the Amended Credit Agreement and the Sixth Amendment to the Royalty Agreement on February 22, 2016, the Company issued to ROS a warrant to purchase 1,673,981 shares of common stock, with an exercise price of $12.50 per share, subject to adjustment for certain events, which may be exercised at any time and from time to time until February 22, 2026. In respect to the consideration provided to ROS in the form of the warrant and the terms of the Eighth Amendment to the Credit Agreement and the Sixth Amendment to the Royalty Agreement, the Company evaluated whether the debt was modified or extinguished pursuant to ASC 470-50, Debt – Modifications and Extinguishments. The Company determined that the previous debt was extinguished and recorded the modified debt at fair value ($51.3 million). The Company recorded a gain on debt extinguishment for the quarter ended March 31, 2016 of $2.9 million which consisted of the remeasurement of the debt at fair value offset by the value of the warrant as of the Counterparty Effective Date and the deferred financing costs previously associated with the term loan. The debt will be accreted to face value over the loan term based on the effective interest rate . In connection with the entering into of the October Counterparty Letter Agreement, on October 24, 2016, the Company Parties and certain of the Company’s other subsidiaries entered into the Ninth Amendment (the “Ninth Amendment to the Credit Agreement”) to the Amended Credit Agreement with the Lender. Pursuant to the Ninth Amendment to the Credit Agreement, the Lender agreed to waive (i) compliance with Section 8.9 of the Amended Credit Agreement solely to permit the entering into of the October Counterparty Letter Agreement, and (ii) any event of default that would occur under Section 9.1(c) of the Amended Credit Agreement solely with respect to the October Counterparty Letter Agreement. In addition, the Ninth Amendment to the Credit Agreement amended the Amended Credit Agreement to provide for the issuance of the Accelerated Convertible Note and the execution of the October Counterparty Letter Agreement. In connection with the issuance of the December 2016 Convertible Note, on December 20, 2016, the Company Parties and certain of the Company’s other subsidiaries entered into the Tenth Amendment (the “Tenth Amendment to the Credit Agreement”) to the Amended Credit Agreement with the Lender. Pursuant to the Tenth Amendment to the Credit Agreement, the Lender consented to the issuance of the December 2016 Convertible Note and the Company agreed to obtain the Lender’s written consent prior to closing on a transaction to sell Company securities to a third party other than the Counterparty or any employee of the Company or Unilife Medical Solutions during the four-month period commencing January 1, 2017 and ending April 30, 2017. There are cross-default provisions in the Amended Credit Agreement, First National Bank loan (as described below), Keystone/CFA Loan (as described below), and the Outstanding Counterparty Notes (as described below), so that a default under one agreement could trigger a default under the others. First National Bank, the Lender under the Amended Credit Agreement, Keystone Redevelopment Group, LLC and Commonwealth Financing Authority are parties to an intercreditor agreement. The Counterparty and the Lender are also parties to an intercreditor agreement. Royalty Agreement In connection with entering into the Credit Agreement, Unilife Medical Solutions entered into a Royalty Agreement with ROS (the “Royalty Agreement”) and, as amended the “Amended Royalty Agreement”, which entitles ROS to receive royalty payments. Unilife Medical Solutions has agreed to pay ROS 4.52% on the first $50.0 million of net sales in each fiscal year, plus 1.75% of net sales in excess of $50.0 million and up to and including $100.0 million in each fiscal year, plus 0.438% of net sales in excess of $100.0 million in each fiscal year. Unilife Medical Solutions has the right to buy out the Amended Royalty Agreement at any time on or before March 12, 2018 at a reduced amount. As of December 31, 2016, the buy-out amount was approximately $27.7 million, on March 13, 2017, the buy-out amount increases to approximately $33.5 million, and on March 13, 2018, the buy-out amount increases up to a maximum of approximately $37.2 million. The buy-out amount varies based on when the buy-out option is exercised and would, in each case, be reduced by amounts previously paid by Unilife Medical Solutions to ROS pursuant to the Amended Royalty Agreement. In the event of default under the Amended Credit Agreement, OrbiMed will have a put option that will make the royalty amounts due immediately. The Amended Royalty Agreement has a term commencing on March 12, 2014 and ending on the earlier of (i) March 12, 2024 and (ii) the date of payment of the purchase price pursuant to the exercise of a put option by the Lender or the exercise of a buy-out option by Unilife Medical Solutions. As the Company has elected to value the Amended Royalty Agreement at fair value, the put option feature does not meet the criterion of ASC 815-15-25-1b and thus is not separated from the host contract and accounted for as a derivative instrument. On February 22, 2016, Unilife Medical Solutions entered into the Sixth Amendment to the Royalty Agreement with ROS. Pursuant to and subject to the terms of the Sixth Amendment to the Royalty Agreement, ROS agreed to waive any rights to royalty payments otherwise payable as a result of the License Fee and the proceeds of the Notes, and to defer royalty payments payable on revenues received by the from the Counterparty until after the end of the first fiscal quarter in which the sells a commercial quantity of devices developed for the Counterparty. At inception, the royalty liability was determined to have a fair value of $7.0 million. The royalty liability will be adjusted to fair value on a quarterly basis. As of December 31, 2016, the fair value of the royalty liability was $5.5 million. Senior Secured Convertible Notes On February 22, 2016, the Company and Unilife Medical Solutions entered into a Securities Purchase Agreement (the “Counterparty SPA”) with Amgen Inc. (the “Counterparty”), pursuant to which Counterparty agreed to purchase from the Company a new series of 6% Senior Secured Convertible Notes Due 2023 in the aggregate original principal amount of up to $55.0 million (the “Notes”). The Notes originally were to be issued in up to three separate closings. The Company issued to the Counterparty the first Note in the aggregate original principal amount of $30.0 million on February 22, 2016 (the “February 2016 Convertible Note”) and Counterparty paid to the Company $30.0 million in exchange therefor . Pursuant to the Counterparty SPA, the Counterparty originally was entitled to purchase two additional Notes in January 2017 (the “2017 Convertible Note”) and January 2018 (the “2018 Convertible Note”) in the amounts of $15.0 million and $10.0 million, respectively. On October 24, 2016, the Company Parties and the Counterparty entered into the October Counterparty Letter Agreement, pursuant to which the Company Parties agreed to issue to the Counterparty on October 24, 2016, in accordance with the terms and conditions of the Counterparty SPA and the October Counterparty Letter Agreement, a portion of the 2017 Convertible Note (the “Accelerated Convertible Note”) in the initial principal amount of $10.0 million plus the $0.6 million financing fee (the “Financing Fee”), for an aggregate initial principal amount of $10.6 million. In consideration for issuing the Accelerated Convertible Note, the Counterparty paid to the Company $10.0 million on October 24, 2016. On December 20, 2016, the Company issued the remaining portion of the 2017 Convertible Note in the aggregate principal amount of $5.0 million (the “December 2016 Convertible Note”) and the Counterparty paid to the Company $5.0 million in exchange therefor. The terms of the December 2016 Convertible Note are substantially the same as those of the February 2016 Convertible Note and the Accelerated Convertible Note . The 2018 Convertible Note will continue to be issuable in January 2018 by the Company Parties to the Counterparty in accordance with the terms and conditions of the Counterparty SPA. There can be no assurance as to when or if the Counterparty will purchase all or any part of the 2018 Convertible Note. Interest under each of the February 2016 Convertible Note, the Accelerated Convertible Note, and the December 2016 Convertible Note (together, the “Outstanding Counterparty Notes”) accrues at a rate of 6% per year and will be paid quarterly in arrears through the addition of the amount of such interest to the then outstanding principal amount. All or part of the principal and accrued interest on each of the Outstanding Counterparty Notes will be repaid through (i) discounted pricing on purchases by the Counterparty of the Company’s products, (ii) credits taken by the Counterparty against development and customization fees for devices, and (iii) credits against per-unit royalties otherwise payable to the Company for the manufacture and sale of the Company’s products. Any repayment will be applied to the Outstanding Counterparty Notes in the order of their issuance. In addition, pursuant to each of the Outstanding Counterparty Notes, the Company has the right to prepay in cash all or part of the principal and accrued interest at any time upon 15 business days’ prior notice, subject to the Counterparty’s conversion right with respect to the contemplated prepayment amount. The Company is required to pay in cash any amounts of principal and accrued interest outstanding at the maturity date of each of the Outstanding Counterparty Notes, which is February 22, 2023 in both instances. During the six months ended December 31, 2016, the Company made non-cash repayments totaling $2.3 million towards the balance of the Outstanding Counterparty Notes. The repayments were for credits relating to development and customization fees. Each of The Counterparty may cause the redemption of the Outstanding Counterparty Notes upon any event of default by the Company. Events of default under the Outstanding Counterparty Notes include, among others, a failure by the Company to convert the applicable note upon proper notice by the Counterparty or pay principal and interest on the applicable note when due; an acceleration of any other indebtedness under the Amended Credit Agreement or other indebtedness of the Company in excess of $1.0 million; a bankruptcy of the Company; a judgment against the Company in excess of $1.0 million; a representation or warranty made in the Counterparty SPA and the related transaction documents is materially false or misleading when made; a material breach by the Company of a covenant or other term or condition in the Counterparty SPA and the related transaction documents; the Counterparty SPA and the related transaction documents cease to be effective; the termination or amendment of the Eighth Amendment to the Credit Agreement or the Sixth Amendment to the Royalty Agreement; and the incurrence of a lien on collateral that is not a permitted lien. The Company is required to redeem for cash each of the Outstanding Counterparty Notes upon a change of control of the Company in an amount equal to 101% of the aggregate principal and accrued interest outstanding as of the change of control. Each of the Outstanding Counterparty Notes also provides the Counterparty with certain rights to acquire additional shares of common stock or other securities or assets of the Company, as applicable, in the event: (i) the Company grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to the holders of common stock; or (ii) the Company makes certain other distributions to Company stockholders such that, in the case of (i) or (ii), the Counterparty receives, in addition to the shares of common stock otherwise issuable upon conversion of the Outstanding Counterparty Notes, the shares of common stock or other securities or assets, as applicable, that the Counterparty would have been entitled to receive if the Counterparty had converted the Outstanding Counterparty Notes into common stock immediately prior to such event. The Outstanding Counterparty Notes are secured by certain inventory and intellectual property assets related to a specific device being licensed to the Counterparty. The Counterparty has agreed to preserve license rights granted to other customers for any license rights granted prior to a foreclosure. The terms and conditions of the 2018 Counterparty Note, if purchased by the Counterparty, are substantially the same as the terms and conditions of the Outstanding Counterparty Notes, except that the “Conversion Rate Floor Price” of the 2018 Counterparty Note will be the greatest of (x) $12.50, (y) the closing sale price of the common stock on the trading day preceding the issuance date, and (z) the book value per share of common stock on the trading day immediately preceding the issuance date. The Company determined that the conversion feature should be accounted for as a stock put option and would be bifurcated from the value of the Outstanding Counterparty Notes and treated as a derivative liability. The initial fair value of the derivative liability of the February 2016 Convertible Note, the Accelerated Convertible Note, and the December 2016 Convertible Note was determined to be $1.7 million, $0.1 million, and less than $0.1 million, respectively. The Outstanding Counterparty Notes will be accreted to their face value over the life of the Note term based on the effective interest rate. On September 29, 2016 July 1, 2017 Counterparty Counterparty On July 28, 2016, the Company and the Counterparty entered into two letter agreements. Pursuant to the first letter agreement, the Counterparty agreed to not convert the Notes into shares of the Company’s common stock to the extent that such conversion would cause the Counterparty to beneficially own 10% or more of the outstanding shares of the common stock immediately following such conversion (the “Conversion Limit”). Pursuant to such letter agreement, the Counterparty has the right to terminate the Conversion Limit at any time with 75 days’ prior written notice to the Company. Pursuant to the second letter agreement, the Counterparty agreed (i) to waive, until 11:59 p.m. New York City time on November 7, 2016, any and all rights whatsoever that the Counterparty had to declare an “Event of Default” under the February As noted above, the Company filed the with the SEC on October 24, 2016. Under section 6.3 of the Counterparty SPA, the Company is required to, until the date on which the Counterparty has sold all the shares of the Company’s common stock into which the Notes are convertible (the “Conversion Shares”) and none of the Notes are outstanding, (i) timely file all reports required to be filed with the SEC pursuant to the Exchange Act or the rules and regulations thereunder and (ii) not take any action or file any document (whether or not permitted by the Securities Act or the rules promulgated thereunder) to terminate or suspend the Company’s reporting and filing obligations under the Exchange Act or Securities Act, (iii) take all actions necessary to maintain the Company’s eligibility to register the Conversion Shares for resale by the Counterparty on Form S-3, and (iv) use its commercially reasonable efforts to take all action as may be required as a condition to the availability of Rule 144 under the Securities Act with respect to the Company’s common stock. Mortgage Loan In October 2010, Cross Farm entered into the Loan Agreement with First National Bank (formerly known as Metro Bank), pursuant to which First National Bank provided Cross Farm with two mortgage loans in the amounts of $14.25 million (“First Mortgage”) and $3.75 million (“Second Mortgage”). The proceeds received were used to finance the purchase of land and construction of the Company’s corporate headquarters and manufacturing facility in York, Pennsylvania. In connection with the credit agreement, the Company entered into the Metro Bank Amendment pursuant to which the Second Mortgage due October 2020 was repaid. Cross Farm is paying principal and interest on the First Mortgage, with interest at a fixed rate of 6.00%. The original First National Bank loan documents contain certain customary covenants, including the maintenance of a debt service reserve account in the amount of $2.4 million, classified as restricted cash on the consolidated balance sheets, which will remain in place until Cross Farm and First National Bank agree on the financial covenants. In addition the Company is required to maintain a cash balance of $5.0 million inclusive of the $2.4 million reserve account. The terms of the original First National Bank loan documents allow the Company to use the debt service reserve account to pay monthly debt service on the mortgage loans, so long as the balance in the account is at least $1.6 million and is replenished to $2.4 million every six months. The Company is in compliance with its debt covenants as of December 31, 2016. However, there can be no assurance that the Company will be able to maintain the debt service reserve account balance for a period of 12 months from December 31, 2016. Cross Farm may prepay the loan without penalty. The U.S. Department of Agriculture has guaranteed $8.0 million of the mortgage loan due December 2031. In connection with the First Mortgage, the Company has given First National Bank a lien on the building and real estate and the debt service reserve account. Commonwealth of Pennsylvania Financing Authority Loan In December 2010, Cross Farm received a $2.25 million loan from Keystone Redevelopment Group, LLC (“Keystone”) for land and the construction of its current manufacturing facility. The loan bears interest at a rate of 5.00% per annum, matures in January 2021 and is secured by a third mortgage on the facility. Keystone assigned the loan and mortgage (the “Keystone/CFA Loan”) to the Commonwealth of Pennsylvania Financing Authority. In connection with the Keystone/CFA Loan, Cross Farm entered into an intercreditor agreement by which the Commonwealth of Pennsylvania agreed that it would not exercise its rights in the event of a default by Cross Farm without the consent of Metro Bank, which holds the first mortgage on the facility. Loan from our Former CEO On September 30, 2015, the Company obtained a loan in the amount of $0.6 million from Alan Shortall, the Company’s former Chairman and Chief Executive Officer. During February 2016, the loan was repaid in full including payment of interest to Mr. Shortall at the minimum applicable federal rate, which interest was less than $0.1 million.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The Company’s net loss per share is as follows: Three Months Ended December 31, Six Months Ended December 31, 2016 2015 2016 2015 (In thousands, except share and per share data) (In thousands, except share and per share data) Numerator Net loss $ (15,309 ) $ (25,423 ) $ (33,282 ) $ (51,287 ) Deemed dividend on Series A Preferred Stock — (1,047 ) — (1,047 ) Net loss attributable to common stock holders $ (15,309 ) $ (26,470 ) $ (33,282 ) $ (52,334 ) Denominator Weighted average number of shares used to compute basic net loss per share 16,698,329 13,377,229 16,672,595 12,915,014 Effect of dilutive options to purchase common stock — — — — Weighted average number of shares used to compute diluted net loss per share 16,698,329 13,377,229 16,672,595 12,915,014 Basic and diluted net loss per share $ (0.92 ) $ (1.98 ) $ (2.00 ) $ (4.05 ) Due to the Company’s net losses, unvested shares of restricted stock (participating securities) totaling 729,434 and 1,007,211 were excluded from the calculation of basic and diluted net loss per share during the three months ended December 31, 2016 and 2015, respectively; and unvested shares of restricted stock (participating securities) totaling 789,889 and 1,035,368 were excluded from the calculation of basic and diluted net loss per share during the six months ended December 31, 2016 and 2015, respectively. In addition, stock options and warrants (non-participating securities) totaling 1,887,797 and 333,189 during the three months ended December 31, 2016 and 2015, respectively, were excluded from the calculation of diluted net loss per share, as their effect would have been anti-dilutive; and stock options and warrants (non-participating securities) totaling 1,887,797 and 319,929 during the six months ended December 31, 2016 and 2015, respectively, were excluded from the calculation of diluted net loss per share, as their effect would have been anti-dilutive. All of these stock options were excluded solely due to the Company’s net loss position. Had the Company reported net income during the three months ended December 31, 2016 and 2015, these shares would have had an effect of 0 and 0 diluted shares, respectively; and had the Company reported net income during the six months ended December 31, 2016 and 2015, these shares would have had an effect of 0 and 0 diluted shares, respectively, for purposes of calculating diluted net income per share. The impact of the potential conversion of outstanding Convertible Notes of 3,605,069 diluted shares as of December 31, 2016 were also excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive.

Contingencies

Contingencies	6 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Contingencies	11. Contingencies From time to time, the Company is involved in various legal proceedings, claims, suits and complaints arising out of the normal course of business. Based on the facts currently available to the Company, management believes that these claims, suits and complaints are adequately provided for, covered by insurance, without merit or that it is not probable that an unfavorable outcome will result. In addition, the Company is or was involved in the following legal proceedings: A former employee, Talbot Smith, who was terminated for cause by the Company, filed a civil complaint in the United States District Court of the Eastern District of Pennsylvania on August 30, 2013, and an amended complaint on March 5, 2014, alleging that he was wrongly terminated in retaliation for making allegations about the Company’s compliance practices. Following the discovery process, Mr. Smith dismissed his claims against the Company with prejudice. In connection with the resolution and dismissal of the action, Mr. Smith agreed to make a payment to the Company to settle counter claims the Company had brought against him. Mr. Smith received no payment as part of the resolution and dismissal of his claims against the Company, his attorney received a reduced portion of her fees from the Company’s insurer, and the matter is now concluded. As previously disclosed, subsequent to the filing of an OSHA complaint by Mr. Smith, we received a subpoena from the staff of the SEC (the “Staff”) requesting the Company to provide certain information to the Staff, which is generally consistent with the meritless allegations made by Mr. Smith in his OSHA complaint. In his complaint filed in the United States District Court for the Eastern District of Pennsylvania, Mr. Smith stated that he provided the Staff with information about his allegations in July and August 2012. The Company responded to that subpoena and has received additional subpoenas and requests for information from the Staff, requesting additional information consistent with the first subpoena. The Staff has also requested information about public statements made by the Company’s former Chief Executive Officer. The Company has provided the requested information to the Staff. On May 8, 2016, the Company announced an investigation into violations of the Company’s policies and procedures and possible violations of laws and regulations by the Company’s former Chief Executive Officer, Alan Shortall, whose employment with the Company ceased on March 11, 2016, and its former Chairman, Jim Bosnjak, who resigned from the Board on August 24, 2015 the Company has reported to the SEC on the Company’s findings from the Investigation, has responded to questions from the Staff regarding the findings, and is cooperating fully with the Staff. what action the SEC or other regulatory authority may take, if any, in relation to these matters or the impact, if any, of any such action on the Company’s business, operations, cash flows and/or financial condition. If any fines or penalties are assessed against the Company, they may be material. On September 14, 2015, Unilife Medical Solutions was served with a complaint filed in the Superior Court of the State of Connecticut by Biodel, Inc. (“Biodel”) seeking (1) to temporarily enjoin Unilife Medical Solutions from entering into a transaction that would jeopardize the Company’s ability to perform its obligations under the Customization and Commercial Supply Agreement effective April 8, 2013 (as amended, the “First Biodel Agreement”) between Biodel and Unilife Medical Solutions; and (2) damages under the Connecticut Unfair Trade Practices Act. Biodel alleged that Unilife Medical Solutions had engaged in unfair and deceptive trade practices by purportedly misrepresenting its ability and willingness to satisfy its obligations under the First Biodel Agreement and requesting additional payments from Biodel to satisfy the Company’s obligations. Additionally, Biodel filed a demand for arbitration with the American Arbitration Association (AAA) asserting that Unilife Medical Solutions had breached its obligations relating to the timing and scope of its performance under the First Biodel Agreement. The Company filed counterclaims in the arbitration for commercial disparagement and breach of the confidentiality provisions of the agreement. On September 2, 2016, Biodel, the Company and Unilife Medical Solutions entered into an Asset Purchase and License Agreement (the “Second Biodel Agreement”) which provides: (a) for the termination of the First Biodel Agreement; (b) for the grant of an exclusive license for a six-month term to the intellectual property rights related to the Unilife mixing device; (c) a six-month term during which Biodel can exercise an option (the “Option”) to purchase certain assets associated with the First Biodel Agreement for $1.5 million (the “Potential Asset Sale”) and extend Biodel’s license, for fees based on intellectual prosecution and maintenance costs determined on an annual basis; (c) dismissal, with prejudice, of all active proceedings in connection with the litigation and arbitration proceedings pending between Biodel and Unilife Medical Solutions. Under the Second Biodel Agreement, each party also released the other party of all liability, waived all claims with prejudice, and forever holds the other party harmless from any damages arising out of relating to the First Biodel Agreement. Biodel and Unilife Medical Solutions each paid their respective attorneys’ fees and Unilife Medical Solutions paid no monetary amount to Biodel in connection with this resolution. To date, Biodel has not exercised the Option. On March 24, 2016, Edward Fine filed a complaint against the Company and Unilife Medical Solutions Limited (“UMSL”) in the Superior Court of New Jersey. The complaint alleges that the Company and UMSL are in breach of contract and have been unjustly enriched as a result of UMSL’s failure to pay certain required payments under a consultancy agreement between Mr. Fine and UMSL. Pursuant to the complaint, Mr. Fine is seeking monetary damages in the amount of $288,000 in the aggregate. The Company believes that Mr. Fine’s claims and demands for relief are wholly without merit and the Company is vigorously defending the action. On August 15, 2016, we filed an Answer, Affirmative Defenses and Counterclaims, wherein we asserted counterclaims against Mr. Fine for fraud, civil conspiracy, unjust enrichment, breach of contract, and breach of the implied covenant of good faith and fair dealing arising out of Mr. Fine’s role in certain previously disclosed transactions involving Mr. Fine and Jim Bosnjak, the Company’s former Chairman of the Board. On September 23, 2016, Mr. Fine filed an Answer and Affirmative Defenses to the Company’s counterclaims. This action is currently in a 450-day discovery period which commenced on July 29, 2016. On May 26 and 27, 2016, two putative class actions were filed in the United States District Court for the Southern District of New York alleging that in violation of Rule 10b-5 and Section 20(a) of the Exchange Act, the Company and six individual defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company’s former CEO and former Chairman of the Board of Directors had violated the Company’s policies and procedures and had engaged in violations of law and regulations; (2) that the Company lacked adequate internal controls over accounting and financial reporting; (3) that, as a result, the Company would be unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2016 by the prescribed filing deadline; and (4) that, as a result of the foregoing, the Company’s financial statements, as well as its statements about the Company’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. The putative class actions were brought on behalf of purchasers of the Company’s securities between February 3, 2014 and May 23, 2016. On August 24, 2016, the Court consolidated the two actions, appointed lead plaintiffs and lead counsel, and set a deadline of October 24, 2016 for Plaintiffs to file an amended complaint. The plaintiffs filed an amended complaint on October 24, 2016 expanding the class to purchasers of the Company’s securities between November 9, 2011 and July 28, 2016, dropping three of the original individual defendants as named defendants and making additional allegations related to matters the Company disclosed in connection with the Investigation. In accordance with a scheduling order issued by the Court on December 12, 2016, Plaintiffs filed a second amended complaint on December 14, 2016 that, among other things, included allegations relating to the Company’s October 24, 2016 and November 14, 2016 SEC filings. In February 2017, the parties reached an agreement-in-principle to fully resolve all claims that were asserted or could have been asserted in the lawsuit. An insurer for the Company has agreed to pay the full amount of the proposed settlement. The proposed settlement is subject to definitive documentation and court approval. If the proposed settlement is not consummated, the Company intends to vigorously contest this lawsuit. The Company has recorded a receivable from its insurance carrier and a liability to the claimants for $4.4 million, which is included in prepaid and other current assets and accrued expenses on the consolidated balance sheet at December 31, 2016 related to this matter. On July 11, July 28, and August 1, 2016, respectively, derivative complaints were filed in the Court of Common Pleas in York County, Pennsylvania against 11 current or former directors and/or officers, alleging (i) breach of their fiduciary duties, (ii) unjust enrichment, (iii) abuse of control, (iv) gross mismanagement, and (v) corporate waste. The complaints allege, among other things, that the individual defendants breached the fiduciary duties they owed to the Company by (1) grossly mismanaging the Company and perpetuating a variety of self-serving schemes to benefit themselves and other interested parties and (2) making and/or causing the Company to make false/misleading statements or omissions of fact in its public disclosures. The complaints further allege that as a result of this alleged conduct, the Company will lose and expend millions of dollars. On January 11, 2017, a derivative complaint was filed in the United States District Court for the Southern District of New York against 11 current or former directors and/or officers that makes similar allegations to those asserted in the previously-filed derivative complaints. In February 2017, the parties reached an agreement-in-principle to fully resolve all claims that were asserted or could have been asserted in these lawsuits which includes the Company’s agreement to make certain modifications to its corporate governance and also a payment to plaintiffs’ attorneys’ for their fees, which an insurer for the Company has agreed to pay. The proposed settlement is subject to definitive documentation and court approval. If the proposed settlement is not consummated, the Company intends to vigorously contest these lawsuits. The Company has recorded a receivable from its insurance carrier and a liability to the claimants for $0.6 million, which is included in prepaid and other current assets and accrued expenses on the consolidated balance sheet at December 31, 2016 related to this matter. On August 17, 2016, Kahle Automation, S.r.l. (“Kahle”) filed a complaint against Unilife Medical Solutions in the United States District Court for the District of New Jersey. The complaint alleges that Unilife Medical Solutions breached contracts with Kahle for Kahle’s supply of automation systems for Unilife Medical Solutions’ Nexus and Finesse product lines. Kahle seeks monetary damages of $4.2 million which includes alleged damages that we believe are not recoverable, such as $0.9 million for bank fees, and $0.8 million for lost profits. Kahle also seeks injunctive relief enjoining Unilife Medical Solutions from using the Nexus System and requiring Unilife Medical Solutions to take delivery of work in process related to the Finesse System. Unilife Medical Solutions disputes Kahle’s allegations that Unilife Medical Solutions terminated its agreement with Kahle for the Finesse System. We intend to defend ourselves vigorously against these claims. The Company received an assessment for approximately $0.3 million for sales and use taxes as a result of an audit by the Commonwealth of Pennsylvania. The Company has appealed the assessment and in connection with the appeal the Commonwealth of Pennsylvania required the Company to post a surety bond in December 2016 in the amount of the assessment. The Company transferred $0.3 million into a restricted cash account as collateral, which is included in restricted cash on the consolidated balance sheet as of December 31, 2016, to support the issuance of the surety bond by a highly rated insurance company. The Company believes that depending on the outcome, certain of these matters may have a material impact to the Company or its business.

Revenue

Revenue	6 Months Ended
	Dec. 31, 2016
Revenue Disclosure [Abstract]
Revenue	12. Revenue The Company recognized $2.3 million and $4.5 million of revenue during the three months ended December 31, 2016 and 2015, respectively. The Company recognized $4.1 million and $7.7 million of revenue during the six months ended December 31, 2016 and 2015, respectively. During the three months ended December 31, 2016, four customers accounted for 41%, 37%, 12% and 10% of consolidated revenue, respectively. During the three months ended December 31, 2015, three customers accounted for 39%, 30% and 25% of consolidated revenue, respectively. During the six months ended December 31, 2016 three customers accounted for 41%, 28%, and 24% of consolidated revenue, respectively. During the six months ended December 31, 2015 four customers accounted for 32%, 28%, 25% and 11% of consolidated revenue, respectively. 2016 During the three and six months months ended December 31, 2016, the Company recognized $0.6 million and $1.0 million of revenue, respectively, related to substantive milestones, as follows: The Company recognized $0.6 million and $1.0 million of revenue during the three and six months ended December 31, 2016 pursuant to a master services and supply agreement with a customer related to substantive milestones that were completed and accepted. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $1.1 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the six months ended December 31, 2016 are as follows: • $0.4 million for development and delivery of components for a human factor study; • $0.4 million for completion of testing of assembly equipment; and • $0.3 million for completion of filling process of clinical devices; The remaining substantive milestones as of December 31, 2016 are as follows: • $0.4 million for delivery of containers for the filling process; and • $0.3 million for delivery of devices for clinical studies. During the three and six months ended December 31, 2016, the Company recognized $1.5 million and $2.7 million in revenue related to services rendered on a time and materials basis, proportional performance method, the completed contract method and/or straight line basis over the requisite service period pursuant to customer agreements to provide various customization and development services. On December 31, 2015, the Company entered into an exclusivity agreement (the “Exclusivity Agreement”) with Amgen Inc. (the “Counterparty”). Pursuant to the Exclusivity Agreement, the Counterparty paid to the Company a non-refundable $15.0 million license fee (the “First License Fee”). The Company and the Counterparty then entered into a License Agreement on February 5, 2016 (the “First License Agreement”) to further define the license rights set forth in the Exclusivity Agreement. Furthermore on February 22, 2016, the Company granted the Counterparty exclusive rights to the Company’s wearable injectors within select drug classes for use with certain assets, while preserving rights the Company previously granted to other customers. The Company has also granted to the Counterparty non-exclusive rights to all of the Company’s proprietary delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience. The Counterparty paid to the Company an additional non-refundable $20.0 million fee (the “Second License Fee”) in consideration for such licenses. 2015 During the three and six months ended December 31, 2015, the Company recognized $2.1 million and $3.9 million of revenue related to substantive milestones, respectively, as follows: The Company recognized $1.2 million and $1.7 million of revenue during the three and six months ended December 31, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $0.1 million was determined to be non-substantive and is being recognized on a straight line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the six months ended December 31, 2015 are as follows: • $0.5 million for development and delivery of additional human factor stimuli and a report on updated product requirements; and • $1.2 million for development and delivery of semi-functional prototypes and related feasibility, product requirement, and risk management reports. The Company recognized $0.9 million and $1.5 million of revenue during the three and six months ended December 31, 2015 pursuant to a master services and supply agreement with a customer related to substantive milestones that were completed and accepted. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $1.1million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the six months ended December 31, 2015 are as follows: • $0.6 million for development and delivery of a complete system layout; • $0.3 million for development and delivery of components for a human factor study; and • $0.6 million for development and delivery of feasibility devices for testing; The remaining substantive milestones as of December 31, 2015 are as follows: • $0.6 million for development and delivery of a clinical production process; • $0.4 million for development and delivery of components for a human factor study; • $0.4 million for completion of testing of assembly equipment; • $0.3 million for completion of filling process of clinical devices; • $0.4 million for delivery of containers for the filling process; and • $0.3 million for delivery of devices for clinical studies. The Company recognized $0.0 million and $0.3 million of revenue during the three and six months ended December 31, 2015 pursuant to a feasibility agreement with a customer related to substantive milestones that were completed and accepted. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon milestones. An initial up-front payment of $0.5 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the six months ended December 31, 2015 are as follows: • $0.3 million for development and delivery of a summary report related to testing and documentation activities. There are no remaining substantive milestones under this agreement. The Company recognized $0.0 million and $0.4 million of revenue during the three and six months ended December 31, 2015 pursuant to a master services and supply agreement with a customer related to substantive milestones that were completed and accepted. This agreement provides for certain customization and development activities for a drug delivery system to be performed for the customer and provides for payments to be made upon the completion of agreed-upon substantive milestones. An initial up-front payment of $1.0 million was determined to be non-substantive and is being recognized on a straight-line basis over the expected term of the agreement. The remaining milestones were determined to be substantive at the time the agreement was entered into. Substantive milestones that were achieved during the six months months ended December 31, 2015 are as follows: • $0.4 million for development and delivery of feasibility devices for testing; The remaining substantive milestones as of December 31, 2015 are as follows: • $0.6 million for delivery of design transfer for the Device and the related filling equipment and fixtures; and • $0.3 million for commissioning of the pilot line. During the three and six months ended December 31, 2015, the Company recognized $2.4 million and $3.8 million in revenue related to services rendered on a time and materials basis, proportional performance method and/or straight line basis over the requisite service period pursuant to customer agreements to provide various customization and development services.

Change in Board of Directors

Change in Board of Directors	6 Months Ended
	Dec. 31, 2016
Change In Board Of Directors [Abstract]
Change in Board of Directors	13. Changes in Board of Directors On October 28, 2016 the Board appointed Rosemary A. Crane and Duane DeSisto to serve as members of the Board. William Galle did not seek re-appointment to the Board at the Company’s 2016 annual meeting of stockholders and therefore resigned from the Board effective as of December 15, 2016.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	14. Fair Value Measurements The Company categorizes its assets and liabilities measured at fair value into a fair value hierarchy that prioritizes the inputs used in pricing the asset or liability. The three levels of the fair value hierarchy are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The levels in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The following table presents the Company’s liabilities that are measured at fair value on a recurring basis for the periods presented: Basis of Fair Value Measurement Total Fair Value Measurements Quoted Market Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) December 31, 2016: Royalty agreement liability $ 5,464 $ — $ — $ 5,464 Warrant liability 2,147 — — 2,147 Derivative liability 457 — — 457 June 30, 2016: Royalty agreement liability $ 5,120 $ — $ — $ 5,120 Warrant liability 3,351 — — 3,351 Derivative liability 347 — — 347 The following table presents the changes in the fair value of the level 3 financial instruments for the six months ended December 31, 2016. Royalty Agreement liability Warrant Liability Derivative Liability June 30, 2016 $ 5,120 $ 3,351 $ 347 Cash payments (41 ) — — Liability recognized on new debt issued during period — — 172 Increase (decrease) in liability 385 (1,204 ) (62 ) December 31, 2016 $ 5,464 $ 2,147 $ 457 Following is a description of the valuation methodologies used to measure the royalty agreement liability, the warrant liability, and the derivative liability. There have been no changes in the methodology used during the six months ended December 31, 2016. The fair value of the royalty agreement liability is based on a discounted cash flow methodology under the income approach based on the present value sum of payments expected to be made in the future. The fair value is estimated by applying a risk adjusted discount rate to the expected royalty payment stream. These fair value estimates are most sensitive to changes in the payment stream and royalty rates. The fair value of the warrant liability is based on a Black-Scholes valuation. The fair value estimates are most sensitive to changes in the Company’s share price. The fair value of the derivative liability is based on the average of a Monte Carlo model and a lattice model. The fair value estimates are most sensitive to changes in the Company’s share price. Other Financial Instruments The carrying amount of the Company’s cash equivalents, which includes certificates of deposit, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short term maturities of these items. The estimated fair value of the Company’s debt approximates its carrying value based upon the terms that the Company would currently be able to receive for similar instruments of comparable maturity.

Sublease

Sublease	6 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Sublease	15. Sublease In June 2016, we subleased a portion (the “Subleased Portion”) of our King of Prussia offices. During the term of the sublease, which commenced on October 1, 2016 and will end on March 31, 2019, the Company will receive an aggregate of approximately $1.3 million in rent with respect to the Subleased Portion. During the same time period, the Company will be obligated under the Company’s lease agreement relating to our King of Prussia offices to pay an aggregate of approximately $1.9 million in rent with respect to the Subleased Portion. Assuming the sublessee exercises its renewal option, the Company will receive approximately an additional $1.9 million over the renewal term of April 1, 2019 through June 30, 2022 and the Company will be obligated under the Company’s lease agreement relating to the King of Prussia Facility to pay an aggregate of approximately $2.5 million over the same time period. The Company ceased using the Subleased Portion as of July 20, 2016. The Company recognized a liability associated with the subleased portion under a cease-use date approach since the subleased portion did not have any future economic benefit to the Company. The liability was measured and recognized at fair value at cease-use date and the fair value was determined based on the present value of the remaining lease obligations, adjusted for the effects of deferred items recognized under the lease, and reduced by sublease rentals as noted above. In determining the fair value of the liability, the Company assumed that the renewal term would be exercised by the sublessee. The amount of the non-cash charge recorded to record the fair value of the liability was $0.7 million. The expected cash flows used to estimate the fair value of the liability was discounted using an interest rate that equates to a risk-free rate adjusted for the effect of the Company’s credit standing. The fair value measurement was categorized as Level 3 based on the fair value hierarchy under ASC Topic 820 – F air Value Measurements and Disclosures Over the life of the expected term of the sublease, the Company expects to incur approximately $0.3 million in expense to accrete the value of the liability based on the difference between the net cash flows and present value of these cash flows. The charges, except as noted above, were included in selling, general and administrative expenses. The following table summarizes the liability and costs paid or settled in connection with the sublease, along with total charges expected to be incurred and cumulative charges incurred to date: Sublease Costs (In thousands) Liability balance as of June 30, 2016 $ — Initial liability measurement 909 Costs incurred and charges to expenses 17 Costs paid or settled (206 ) Liability balance as of December 31, 2016 $ 720 Total charges expected to be incurred $ 1,599 Cumulative charges incurred to date $ 1,310

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions Loan from Mr. Shortall On September 30, 2015, the Company obtained a loan in the amount of $600,000 from Alan Shortall, the Company’s former Chairman and Chief Executive Officer. During February 2016, the loan was repaid in full including payment of interest to Mr. Shortall at the minimum applicable federal rate, which interest was less than $2,000. Bosnjak Mortgage Correspondence In July 2015, Mr. Shortall and Mr. Bosnjak, without authorization from or knowledge of the Company or its Board, caused to be transmitted to a mortgage broker for Mr. Shortall from Mr. Bosnjak correspondence that contained inaccurate statements about the Company’s financial support for Mr. Shortall’s purchase of and relocation to a new home. The investigation into the matters described in this paragraph did not identify any financial loss to the Company and the Company has corrected the inaccurate statements to the mortgage broker. Shortall Fund Transfers Mr. Shortall deposited $2,264,475 of his own funds into the Company’s bank account on June 29, 2015 and then caused the Company to disburse from the Shortall Funds $1,351,553 to third parties to complete Mr. Shortall’s purchase of his new home on July 23, 2015, and the remainder back to himself on July 28, 2015. For the six months ended December 31, 2015, under Mr. Shortall’s direction, the Company accepted a check from Mr. Shortall in the aggregate amount of approximately $6,000 and disbursed the same amount of funds to Mr. Shortall’s designee but did not deposit such check from Mr. Shortall until nineteen days after the Company’s disbursement of the funds. The Company believes such transaction constituted a loan from the Company to Mr. Shortall. There were no such transactions for the three and six month periods ended December 31, 2016, or for the three months period ended December 31, 2015. Bosnjak Loan Payments and Unreimbursed Personal Expenses For the six months ended December 31 2015, Mr. Shortall caused approximately $ There were no such transactions for the three and six month periods ended December 31, 2016, or for the three month period ended December 31, 2015. For the three and six months ended December 31, 2015, Mr. Shortall caused the Company to pay for personal expenses of which approximately $200 and $600, respectively were not repaid to the Company (the “Unreimbursed Personal Expenses”). The Company believes the Unreimbursed Personal Expenses constituted loans from the Company to Mr. Shortall, and the Company has demanded repayment of the Unreimbursed Personal Expenses. The collection of such amounts was uncertain and the Company recorded approximately $200 and $600 as Selling, General and Administrative Expense in the three and six months ended December 31, 2015. Advanced Withholding Payments In July 2015, in connection with the vesting of restricted shares of the Company’s common stock, the Company paid associated withholding taxes on behalf of two executive officers, its Vice President of Quality and Regulatory Affairs and Chief Compliance Officer and its former President and Chief Operating Officer, in an aggregate amount of approximately $126,000 prior to being reimbursed by such executive officers. Such executive officers repaid the Company in full within a range of 18 to 28 days from the date of the withholding payment and before September 30, 2015. The Company believes such advances constituted loans. There were no such loans during the three and six months ended December 31, 2016.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Unilife Corporation and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The estimates are principally in the areas of revenue recognition, royalty liability valuation, derivative liability valuation, warrant liability valuation, preferred stock conversion liability (the “Preferred Stock Conversion”) valuation, share-based compensation expense, restructuring obligations, contingencies, recoverability of goodwill, long-lived assets and useful lives of property, plant and equipment. Management bases its estimates on historical experience and various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, including significant improvements, are recorded at cost, net of accumulated depreciation and amortization. Repairs and maintenance are expensed as incurred. Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease Interest cost incurred in connection with the development and construction of significant new machinery and equipment, as well as facility related costs have been capitalized as one of the elements of cost and are being amortized over the asset’s respective useful life. The Company evaluates the recoverability of the recorded value of long-lived assets periodically to determine if facts and circumstances exist that would indicate that the assets might be impaired or that the useful lives should be modified. As part of this valuation, the Company develops projections of undiscounted future cash flows of the asset or asset group. The projections of undiscounted cash flows include a combination of revenue from customization and development activities, capital expenses that may be necessary to support projected product sales and commercial product sales. As customization and development activities are completed, commercial product sales are expected to scale-up. Expectations of future commercial product sales included in the projections used for the impairment analysis are based on customer-specific information as well as market estimates relating to the anticipated drugs and therapies being targeted for use with the Company’s products. These projections also include assumptions of future sales growth and profitability based on contracts entered into with customers as well as future contracts to be entered into based on the current discussions and negotiations with existing and prospective customers. Sales projections are based on assumptions including a transition in the market toward patient self-administration of injectable therapies as well as transitions in the market toward biological-based drugs in the pharmaceutical industry development pipeline. The Company’s future sales could also be impacted by factors such as its ability to obtain new and retain existing customers, the timing and extent of the customers’ drug development activities as well as the regulatory approval process, drug efficacy and industry acceptance of injectable therapies. If the Company’s future sales or its projections of future sales are impacted by any one or more of the preceding factors, it will reassess the recorded value of the long-lived assets. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value. In connection with the Company’s focus on wearable injector products, the Company evaluated the prospects of its non-wearable injector customer and supplier programs in fiscal year 2016. As a result of negotiations related to those supplier and customer programs and the Company’s evaluation of those programs and potential disposition of certain assets, the Company determined that certain of its long lived-assets were impaired and the Company incurred a $26.6 million non-cash asset impairment charge primarily related to machinery and equipment and construction in process in the third quarter of fiscal 2016. There were no asset impairment charges for the three and six months ended December 31, 2016 and 2015.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill is the excess of purchase price over the fair value of net assets acquired in business acquisitions. Goodwill is subject to, at a minimum, an annual impairment assessment of its carrying value at the reporting unit level. Additional impairment assessments would be performed if events and circumstances warranted such additional assessments during the year. The Company has one reporting unit which includes its product lines, the base technology which it obtained as part of its November 2002 acquisition of Unitract Syringe Pty Limited, and the manufacturing capability which it obtained in its January 2007 acquisition of Integrated BioSciences, Inc. As required under GAAP, the Company is required to evaluate goodwill for impairment at least annually and more frequently if certain trigger events occur. The Company determined that the continuing losses incurred by the Company and its negative equity, and the decline in the Company’s stock price constituted trigger events that occurred in the six months ended December 31, 2016 requiring an evaluation of the carrying value of the Company’s goodwill. Potential impairment of goodwill is identified by comparing the fair value with its carrying value. The Company performed a goodwill valuation during the interim period as of September 30, 2016 using a combination of the market approach and a discounted cash flow method under the income approach. The Company determined an overall business enterprise value (determined by the fair of equity plus the fair value of debt) by taking a weighted average from the results of the discounted cash flow under the income approach (40%) and the market approach based on the Company’s market capitalization (60%). Under the income approach, the Company calculates the fair value of its reporting unit based on the present value of estimated future cash flows. Management judgment is necessary to evaluate the impact of operating and external market changes and to estimate the future cash flows used to measure fair value. The Company’s estimate of cash flows considers past performance, current and anticipated market conditions, and internal projections and operating plans which incorporate estimates for sales growth, profitability and capital spending. Additional assumptions include forecasted growth rates and estimated discount rates which are risk adjusted for current market conditions. The Company believes such assumptions reflect current and anticipated market conditions and are consistent with those that would be used by other marketplace participants for similar purposes but are subject to change due to changing conditions. The weighting of the results of each method to assess the overall business enterprise value was considered reasonable as greater weight was given to the market capitalization based on the quoted stock price as this is considered more reliable information as it is publicly available and not subject to management judgment or estimate, whereas, discounted cash flow under the income approach is subject to management estimates and judgments. Although based on the results of the business enterprise value calculation there was no indication of impairment of goodwill, the Company determined as a result of the continuing losses incurred by the Company and its negative equity, and other indicators of impairment and the decline in the Company’s stock price, that an additional step 2 analysis was warranted under generally accepted accounting principles. The Company performed a Step 2 valuation of goodwill by valuing certain intangible assets (primarily patents, trademarks and tradenames). The Company considered the impact of all assets and liabilities in allocating the fair value of the Company to determine the fair value of goodwill and whether any impairment is indicated. The Company believes these intangible assets would generate the most significant difference between implied fair value and book value as part of completing a Step 2 purchase price allocation for the purpose of determining the value of goodwill for impairment. The valuation of intangible assets was performed using the relief from royalty method under the income approach. This method utilizes the Company’s revenue projections and assigns values based on determination of appropriate royalty rates considering relevant industry information. The Company then utilized the fair value of its intangible assets along with the estimated fair value of its other assets and liabilities to determine the implied goodwill compared to the carrying value of goodwill. The residual fair value based on the results of the Step 2 valuation indicated there was no impairment of goodwill. The Company performed a qualitative review through December 31, 2016 and no events occurred or circumstances changed that would more likely than not reduce the fair value of the goodwill below its carrying value. The Company considered that the results of the valuation of goodwill indicated there was no impairment of goodwill and also indicated significant cushion between the implied fair value of goodwill and its carrying value and, therefore, the Company has concluded that no goodwill impairment existed as of December 31, 2016. Definite-lived intangible assets include patents which are amortized on a straight-line method over their estimated useful lives of 15 years and are included in other assets. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate a possible impairment, if the sum of the estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset is less than the carrying amount of the asset, an impairment may be recognized. Measurement of an impairment loss is based on the excess of the carrying value of the asset over its fair value. Definite-lived intangible assets were less than $0.1 million as of December 31, 2016 and June 30, 2016 and are recorded in other assets on the consolidated balance sheet. There were no impairments recorded on intangible assets during the three and six months ended December 31, 2016 and 2015.
Share-Based Compensation	Share-Based Compensation The Company grants equity awards to its employees, directors, consultants and service providers. Certain employee and director awards vest over stated vesting periods and others also require achievement of specific performance or market conditions. The Company expenses the grant-date fair value of awards to employees and directors over their respective vesting periods. To the extent that employee and director awards vest only upon the achievement of a specific performance condition, expense is recognized over the period from the date management determines that the performance condition is probable of achievement through the date they are expected to be met. Awards granted to consultants and service providers are sometimes granted for past services, in which case their fair value is expensed on their grant date, while other awards require future service, or the achievement of performance or market conditions. Timing of expense recognition for consultant awards is similar to that of employee and director awards; however, aggregate expense is re-measured each quarter-end based on the then fair value of the award through the vesting date of the award. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, with the exception of market-based grants, which are valued based on the Monte Carlo option pricing model. Option pricing methods require the input of highly subjective assumptions, including the expected stock price volatility.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from industrialization and development fees, licensing fees and product sales. The Company recognizes revenue from sales of products at the time of shipment when title passes to the customer. The Company recognizes up front, non-refundable fees ratably over the expected life of the related agreement. The Company recognizes license revenue over the life of the patents of the products relating to the license. Revenue from industrialization and development fees is recognized as services are rendered, under the completed contract method, under the proportional performance method or upon achievement of the “at risk” substantive milestone events, which represent the culmination of the earnings process related to such events. Substantive milestones can include specific deliverables such as product design, prototype availability, user tests, manufacturing proof of principle and the various steps to complete the industrialization of the product. The terms of these contracts provide for customer payments to be made as services are rendered or when substantive milestones are achieved. The Company considers whether a milestone is substantive at the inception of the agreement. The consideration earned from the achievement of a milestone must meet all of the following criteria to be considered substantive: • It is commensurate with either of the Company’s performance to achieve the milestone, or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; • It relates solely to past performance; and • It is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Payment terms are considered to be standard commercial terms. Revenue is recognized when each substantive milestone has been achieved and the Company has no future performance obligations related to the substantive milestone. Fees for completed, substantive milestones, which are dependent upon customer acceptance for non-refundable payment or, if paid, are refundable pending customer acceptance are recognized upon customer acceptance or the termination of refund rights.
Fair Value Measurements	Fair Value Measurements In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, the Company measures fair value based on a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. The fair value hierarchy is broken down into three levels based on the source of inputs. The carrying value of financial instruments such as accounts receivable, accounts payable and accrued expenses are reasonable estimates of their fair value because of the short maturity of these items. The Company believes that the current carrying amount of its long-term debt approximates fair value because the terms on these instruments are similar to those terms that the Company would currently be able to receive for similar instruments of comparable maturity. The Company has elected to measure its royalty agreement liability at fair value in accordance with ASC 825, Financial Instruments. The fair value of the royalty liability is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses a methodology and assumptions that the Company believes would be made by a market participant. In particular, the valuation analysis uses a discounted cash flow methodology under the income approach based on the present value sum of payments to be made in the future. The fair value of the royalty agreement liability is estimated by applying a risk adjusted discount rate to the adjusted royalty revenue stream. These fair value estimates are most sensitive to changes in the payment stream. The Company accounts for derivative financial instruments in accordance with ASC 815, Derivative and Hedging — Contracts in Entity’s Own Equity. Instruments which do not have fixed settlement provisions are deemed to be derivative instruments and are valued based on an average of a Monte Carlo and lattice model. The Preferred Stock Conversion valuation analysis used the estimated dividend rate based on the volume-weighted average price of the Company’s common stock at the date the Preferred Stock Conversion is measured. The warrant liability is valued using a Black-Scholes option-pricing model.
Interest Expense	Interest Expense The Company recognizes interest expense in the consolidated statements of operations and comprehensive loss for all debt instruments using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating the interest expense over the relevant period. The effective interest rate is the rate that exactly discounts the estimated future cash payments through the expected life of the financial instrument to the net carrying amount of the financial liability. The application of the method has the effect of recognizing expense payable on the instrument evenly in proportion to the amount outstanding over the period to maturity or repayment. In calculating the effective interest rate, the Company estimates cash flows considering all contractual terms of the financial instrument, including fees for early redemption and all other premiums and discounts.
New Accounting Pronouncements Effective During the Period	New Accounting Pronouncements Effective During the Period In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12 “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved After the Requisite Service Period” which is part of ASC 718: Compensation-Stock Compensation. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and not be reflected in the estimate of the grant-date fair value of the award. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The guidance became effective July 1, 2016 and the Company elected to apply the guidance prospectively for all awards granted or modified after the effective date. The adoption of the new guidance did not have a material impact on the Company’s financial condition, results of operations or cash flows.
New accounting pronouncements not yet adopted	New Accounting Pronouncements Not Yet Adopted In May 2014, FASB issued ASU 2014-09 “Revenue from Contracts with Customers” and amended by ASU 2016-08 “Principle versus Agent Considerations”, ASU 2016-10 “Identifying Performance Obligations and Licensing”, and ASU 2016-12 “Narrow-Scope Improvements and Practical Expedients”. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers” which deferred the effective date of ASU 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Early application is permitted only as of annual periods beginning after December 15, 2016, including interim reporting periods within that reporting period. With the deferral, the new standard is effective for the Company, on July 1, 2018, with early adoption permitted one year prior. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has reviewed the new standards and has begun to consider the impact of the standard on its ongoing financial reporting, but has not yet made any conclusions. In August 2014, FASB issued ASU 2014-15 “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The guidance requires an entity to perform a going concern assessment by evaluating its ability to meet its obligations for a look-forward period of one year from the financial statement issuance date. Disclosures are required if it is probable an entity will be unable to meet its obligations within the look-forward period. Incremental substantial doubt disclosure is required if the probability is not mitigated by management’s plans. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, results of operations and cash flows. In November 2015, the FASB issued new guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the new guidance. The new guidance is effective for the Company on July 1, 2017, with early adoption permitted as of the beginning of an interim or annual reporting period. The new guidance may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company is evaluating the impact that the new guidance will have on its consolidated financial statements and related disclosures; however, at the present time the Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred. In January 2016, the FASB issued new guidance related to the recognition and measurement of financial assets and liabilities. The new guidance makes targeted improvements to GAAP impacting equity investments (other than those accounted for under the equity method or consolidated), financial liabilities accounted for under the fair value election, and presentation and disclosure requirements for financial instruments, among other changes. The new guidance is effective for the Company on July 1, 2018, with early adoption prohibited other than for certain provisions. The Company is evaluating the impact that the new guidance will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. The principal change under the new accounting guidance is that lessees under leases classified as operating leases will recognize a right-of-use asset and a corresponding lease liability. Current lease accounting does not require lessees to recognize assets and liabilities arising under operating leases on the balance sheet. Under the new guidance, lessees (including lessees under leases classified as finance leases and operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Expense recognition and cash flow presentation guidance will be based upon whether the lease is classified as an operating lease or a finance lease (the classification criteria for distinguishing between finance leases and operating leases is substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current guidance). The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company has reviewed the new standard, has begun to identify its contracts that might be impacted by the standard, and has begun to consider the impact of the standard on its ongoing financial reporting, but has not yet made any conclusions. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including guidance relating to accounting for income taxes with respect to share-based payment awards; providing generally that excess tax benefits related to share-based awards should be recorded as a reduction to income tax expense (currently, excess tax benefits generally are recorded to additional-paid-in-capital); providing generally that excess tax benefits related to share-based awards should be classified along with other income tax cash flows as an operating activity (currently, excess tax benefits generally are separated from other income tax cash flows and classified as a financing activity); providing that an entity may make an accounting policy election either to base compensation cost accruals on the number of awards expected to vest (as required by current guidance) or to account for forfeitures when they occur; modifying the current exception to liability classification such that partial cash settlement of an award for tax withholding purposes would not result, by itself, in liability classification of the award if the amount withheld does not exceed the maximum statutory tax rate in the employees' applicable jurisdictions (currently, an award cannot qualify for equity classification, rather than liability classification, if the amount withheld exceeds the minimum statutory withholding requirements); and providing that cash paid by an employer when directly withholding shares for tax withholding purposes should be classified as a financing activity on the statement of cash flows (currently there is no authoritative guidance addressing this classification issue). The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted (if early adoption occurs in an interim period, any adjustments will be reflected as of the beginning of the fiscal year that includes the interim period). Depending on the particular issue addressed by the guidance, application of the guidance will be made prospectively, retrospectively or subject to a retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on the Company's results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows, Clarification of Certain Cash Receipts and Cash Payments”, which provides guidance on the presentation and classification of eight specific cash flow issues. Those issues are cash payment for debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instrument or other debt instrument with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; cash received from settlement of corporate-owned life insurance policies; distribution received from equity method investees; beneficial interest in securitization transactions; and classification of cash receipts and payments that have aspect of more than one class of cash flows. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017 with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash”. The amendments in this Update require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The amendments in this Update should be applied using a retrospective transition method to each period presented. The Company is currently evaluating the impact this guidance will have on its financial disclosures; however, as the guidance only impacts disclosure and cash flows, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, and results of operations. In January 2017, the FASB issued ASU No. 2017-04 “Simplifying the Test for Goodwill Impairment”. The amendments in this Update modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. To simplify the subsequent measurement of goodwill, the FASB eliminated Step 2 from the goodwill impairment test. Under the amendments in this Update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. For public entities, the amendments in this Update are effective on a prospective basis for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. Upon adoption, the Company will be required to disclose the nature of and reason for the change in accounting principle upon transition and that disclosure should be provided in the first annual period and in the interim period within the first annual period when the entity initially adopts the amendments. The Company is currently evaluating the impact of these amendments; however, the adoption of this guidance is not expected to have any impact on the Company’s financial condition, results of operations and cash flows.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Estimated Useful Life of Asset	Depreciation and amortization expense is recorded on a straight-line method over the estimated useful life of the asset as listed below: Asset Category Useful Lives Building 40 years Machinery and equipment 2 to 15 years Computer software 3 to 7 years Furniture and fixtures 3 to 7 years Leasehold improvements Shorter of leasehold improvement life or remaining term of lease

Equity Transactions and Share25

Equity Transactions and Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Options Activity by Employees and Directors	The following is a summary of activity related to stock options held by employees and directors during the six months ended December 31, 2016: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of July 1, 2016 102,552 $ 40.10 Cancelled (8,686 ) 49.25 Outstanding as of December 31, 2016 93,866 39.25 5.5 $ 0 Exercisable as of December 31, 2016 78,366 $ 39.79 5.3 $ 0
Schedule of Stock Options Activity by Persons Other than Employees and Directors	The following is a summary of activity related to stock options and warrants held by persons other than employees and directors during the six months ended December 31, 2016: Number of Options & Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Outstanding as of July 1, 2016 1,793,981 $ 12.68 Granted — — Expired — — Outstanding as of December 31, 2016 1,793,981 $ 12.68 8.8 $ — Exercisable as of December 31, 2016 1,793,981 $ 12.68 8.8 $ —
Summary of Activity Related to Awards of Restricted Stock and Restricted Stock Units	The following is a summary of activity related to awards of restricted stock and restricted stock units during the six months ended December 31, 2016: Number of Restricted Stock Awards and Units Weighted Average Grant Date Fair Value Unvested as of July 1, 2016 882,948 $ 15.41 Granted 313 2.78 Vested (103,087 ) 29.33 Cancelled (94,159 ) 7.33 Unvested as of December 31, 2016 686,015 $ 14.42

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Components of Property, Plant and Equipment	Property, plant and equipment consist of the following: December 31, 2016 June 30, 2016 (in thousands) Building $ 32,362 $ 32,362 Machinery and equipment 20,090 19,537 Computer software 2,986 2,986 Furniture and fixtures 792 1,386 Construction in progress 13,385 13,870 Land 2,036 2,036 Leasehold improvements 349 437 72,000 72,614 Less: accumulated depreciation and amortization (19,691 ) (17,841 ) Property, plant and equipment, net $ 52,309 $ 54,773

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill during the six months ended December 31, 2016 are as follows: (in thousands) Balance as of July 1, 2016 $ 9,423 Foreign currency translation (287 ) Balance as of December 31, 2016 $ 9,136

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Components of Accrued Expenses	Accrued expenses consist of the following: December 31, 2016 June 30, 2016 (In thousands) Accrued payroll and other employee related expenses $ 3,109 $ 2,755 Accrued cost related to equipment 1,320 2,623 Accrued transaction costs 4,000 5,000 Accrued professional fees 964 2,010 Accrued other 6,501 1,322 Total accrued expenses $ 15,894 $ 13,710

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consists of the following: December 31, 2016 June 30, 2016 (In thousands) 10.25% Term loan, due March 2020 $ 64,303 $ 57,227 Royalty agreement liability 5,464 5,120 6.00% Senior secured convertible note, due February 2023 43,428 29,066 6.00% Mortgage loan, due December 2031 12,139 12,370 5.00% Commonwealth of Pennsylvania financing authority loan, due January 2021 1,948 1,977 127,282 105,760 Less: unamortized debt discounts and issuance costs (1,177 ) (646 ) 126,105 105,114 Less: current portion of long-term debt (702 ) (669 ) Total long-term debt $ 125,403 $ 104,445

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	The Company’s net loss per share is as follows: Three Months Ended December 31, Six Months Ended December 31, 2016 2015 2016 2015 (In thousands, except share and per share data) (In thousands, except share and per share data) Numerator Net loss $ (15,309 ) $ (25,423 ) $ (33,282 ) $ (51,287 ) Deemed dividend on Series A Preferred Stock — (1,047 ) — (1,047 ) Net loss attributable to common stock holders $ (15,309 ) $ (26,470 ) $ (33,282 ) $ (52,334 ) Denominator Weighted average number of shares used to compute basic net loss per share 16,698,329 13,377,229 16,672,595 12,915,014 Effect of dilutive options to purchase common stock — — — — Weighted average number of shares used to compute diluted net loss per share 16,698,329 13,377,229 16,672,595 12,915,014 Basic and diluted net loss per share $ (0.92 ) $ (1.98 ) $ (2.00 ) $ (4.05 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measured on Recurring Basis	The following table presents the Company’s liabilities that are measured at fair value on a recurring basis for the periods presented: Basis of Fair Value Measurement Total Fair Value Measurements Quoted Market Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) December 31, 2016: Royalty agreement liability $ 5,464 $ — $ — $ 5,464 Warrant liability 2,147 — — 2,147 Derivative liability 457 — — 457 June 30, 2016: Royalty agreement liability $ 5,120 $ — $ — $ 5,120 Warrant liability 3,351 — — 3,351 Derivative liability 347 — — 347
Schedule of Changes in Fair Value of Level 3 Financial Instruments	The following table presents the changes in the fair value of the level 3 financial instruments for the six months ended December 31, 2016. Royalty Agreement liability Warrant Liability Derivative Liability June 30, 2016 $ 5,120 $ 3,351 $ 347 Cash payments (41 ) — — Liability recognized on new debt issued during period — — 172 Increase (decrease) in liability 385 (1,204 ) (62 ) December 31, 2016 $ 5,464 $ 2,147 $ 457

Sublease (Tables)

Sublease (Tables)	6 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Summary of Liability and Cash Costs Paid or Settled in Connection With Sublease, Total Charges Expected to be Incurred and Cumulative Charges Incurred to Date	The following table summarizes the liability and costs paid or settled in connection with the sublease, along with total charges expected to be incurred and cumulative charges incurred to date: Sublease Costs (In thousands) Liability balance as of June 30, 2016 $ — Initial liability measurement 909 Costs incurred and charges to expenses 17 Costs paid or settled (206 ) Liability balance as of December 31, 2016 $ 720 Total charges expected to be incurred $ 1,599 Cumulative charges incurred to date $ 1,310

Internal Investigation and Li33

Internal Investigation and Listed Exchange Update - Additional Information (Detail) - USD ($)	Oct. 17, 2016	Dec. 31, 2016	Jun. 30, 2016
Revisions To Financial Statements [Abstract]
Description of information letter received from listing qualifications department	On October 17, 2016, the Company received a notice from the Listing Qualifications department of NASDAQ stating that, because the Company did not maintain a minimum Market Value of Listed Securities (“MVLS”) of $50.0 million for the last 30 consecutive business days, the Company was no longer in compliance with NASDAQ Listing Rule 5450(b)(2)(A). The Company has been provided a period of 180 calendar days, or until April 17, 2017, to regain compliance with the minimum MVLS listing requirement. If at any time on or before April 17, 2017, the MVLS of the Company’s common stock, par value $0.01 per share (“common stock”), closes at $50.0 million or more for a minimum of 10 consecutive business days, NASDAQ will provide the Company with written confirmation that the Company has achieved compliance with the minimum MVLS listing requirement and the matter will be closed.
Minimum market value of listed securities	$ 50,000,000
Minimum market value of listed securities violation period as per the listing rule	30 days
Period to regain compliance with NASDAQ	180 days
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
NASDAQ minimum market value of listed securities requirement	$ 50,000,000
Consecutive period of minimum market value of listed securities or above to regain listing compliance	10 days

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	Dec. 20, 2016	Oct. 24, 2016	Feb. 29, 2016	Feb. 22, 2016	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015
Liquidity And Capital Resources [Line Items]
Cash and cash equivalents					$ 9,309,000	$ 18,702,000	$ 17,971,000	$ 12,303,000
Restricted cash					2,700,000
Long-term debt					126,105,000	105,114,000
Working capital (deficit)					(3,100,000)
Cash and restricted cash balance required for credit facility					5,400,000
Proceeds from the issuance of note					15,000,000
Aggregate initial principal amount of debt					127,282,000	105,760,000
March 2017 [Member]
Liquidity And Capital Resources [Line Items]
Cash and restricted cash balance required for credit facility					5,100,000
Up-front Payment Arrangement [Member]
Liquidity And Capital Resources [Line Items]
Long-term deferred revenue					10,000,000
Potential repayments of long term debt					$ 10,000,000
6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member]
Liquidity And Capital Resources [Line Items]
Proceeds from the issuance of note				$ 30,000,000
6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member] | 2017 Convertible Note [Member]
Liquidity And Capital Resources [Line Items]
Maximum amount of notes purchased				15,000,000
6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member] | 2018 Convertible Note [Member]
Liquidity And Capital Resources [Line Items]
Maximum amount of notes purchased				$ 10,000,000
Senior Secured Convertible Notes [Member] | Counterparty [Member]
Liquidity And Capital Resources [Line Items]
Debt weighted average price			90.00%
Number of trading days			20 days
Senior Secured Convertible Notes [Member] | Counterparty [Member] | Conversion Rate Floor Price [Member]
Liquidity And Capital Resources [Line Items]
Debt instrument convertible, conversion price			$ 12.50
Senior Secured Convertible Notes [Member] | 6.00% Senior Secured Convertible Note, Due February 2023 [Member]
Liquidity And Capital Resources [Line Items]
Long-term debt, percentage					6.00%
Long-term debt, due year and month					2023-02
Aggregate initial principal amount of debt					$ 43,428,000	$ 29,066,000
Senior Secured Convertible Notes [Member] | 6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member]
Liquidity And Capital Resources [Line Items]
Long-term debt, percentage			6.00%
Long-term debt, due year and month					2023-02
Senior Secured Convertible Notes [Member] | 6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member] | Maximum [Member]
Liquidity And Capital Resources [Line Items]
Principal amount of debt			$ 55,000,000
Senior Secured Convertible Notes [Member] | October Counterparty Letter Agreement [Member] | 2017 Convertible Note [Member]
Liquidity And Capital Resources [Line Items]
Principal amount of debt		$ 10,000,000
Proceeds from the issuance of note		10,000,000
Financing fee		600,000
Aggregate initial principal amount of debt		$ 10,600,000
Senior Secured Convertible Notes [Member] | December 2016 Convertible Note [Member] | 2017 Convertible Note [Member]
Liquidity And Capital Resources [Line Items]
Principal amount of debt	$ 5,000,000
Proceeds from the issuance of note	5,000,000
Aggregate initial principal amount of debt	$ 5,000,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Estimated Useful Life of Asset (Detail)	6 Months Ended
	Dec. 31, 2016
Building [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	40 years
Machinery and Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	2 years
Machinery and Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	15 years
Computer Software [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Computer Software [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life	7 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Leasehold improvements	Shorter of leasehold improvement life or remaining term of lease

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended			6 Months Ended
	Dec. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)Unit	Dec. 31, 2015USD ($)	Sep. 30, 2016	Jun. 30, 2016USD ($)
Summary Of Significant Accounting Policies [Line Items]
Assets impairment charges	$ 0	$ 26,600,000	$ 0	$ 0	$ 0
Number of reporting units | Unit				1
Goodwill impairments				$ 0
Estimated useful life of intangible assets				15 years
Impairments recorded on intangible assets	0		$ 0	$ 0	$ 0
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Definite-lived intangible assets	$ 100,000			$ 100,000			$ 100,000
Income Approach [Member]
Summary Of Significant Accounting Policies [Line Items]
Fair value of overall business enterprise value, weighted average percentage						40.00%
Market Approach [Member]
Summary Of Significant Accounting Policies [Line Items]
Fair value of overall business enterprise value, weighted average percentage						60.00%

Equity Transactions and Share37

Equity Transactions and Share-Based Compensation - Additional Information (Detail) - USD ($)

Feb. 22, 2016

Feb. 11, 2016

Feb. 03, 2016

Jan. 04, 2016

Nov. 09, 2015

Jan. 31, 2017

Dec. 31, 2016

Jan. 31, 2016

Dec. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Mar. 31, 2016

Jun. 30, 2016

Jul. 29, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

$ 1,200,000

$ 3,400,000

$ 2,200,000

$ 7,000,000

Common stock issued price, net of issuance costs

$ 9,387,000

Number of stock options granted

0

0

0

0

Warrant liability

$ 2,147,000

$ 2,147,000

$ 2,147,000

$ 3,351,000

Options exercised

0

0

Preferred stock, par value

$ 0.01

$ 0.01

$ 0.01

$ 0.01

Preferred stock, shares issued

0

0

0

0

Face value

Period of trading days to no trigger events

3 days

Period of trading days to trigger events

30 days

Description on dividend rate adjustment

The Dividend Rate was adjusted (i) downward by an amount equal to 100 basis points for each amount, if any, equal to $0.50 per share of common stock that the volume weighted average price of our common stock on any trading day rose above $15.00, down to a minimum of 0.0%; and (ii) upward by an amount equal to 150 basis points for each amount, if any, equal to $0.50 per share of common stock that volume weighted average price of our common stock on any trading day fell below $7.00, up to a maximum of 15.0%. In addition, the Dividend Rate was adjusted upward by 10.0% upon any Trigger Event.

Proceeds from the issuance of preferred stock, net of issuance costs

$ 7,200,000

$ 7,172,000

Preferred stock conversion value

$ 0

First Amendment to Preferred Stock Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of redeemable convertible preferred stock, shares

106,668

725,000

Common stock additional shares issuable

831,668

Aggregate potential offering of common stock

2,784,693

Initial Conversion Notices [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Cash issued upon conversion

$ 300,000

Series A Preferred Stock [Member] | Initial Conversion Notices [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of stock, shares converted

300

Series A Preferred Stock [Member] | January 4th Conversion Notice and Initial Conversion Notices [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of stock, shares converted

40

Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant period related to purchase of common stock

5 years

Warrants to repurchase common stock

90,000

Exercise price of warrants

$ 10

Warrant per common stock

5.40

$ 0.79

Warrant liability revalued

100,000

100,000

$ 100,000

Investor [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Notice period

61 days

Credit Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants to repurchase common stock

1,673,981

Exercise price of warrants

$ 12.50

Warrant per common stock

$ 7.20

$ 1.24

Warrant liability revalued

$ 2,100,000

$ 2,100,000

$ 2,100,000

Warrant liability

12,100,000

Warrants [Member] | Purchase Agreement with Lincoln Park Capital Fund, LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

$ 500,000

Series A Redeemable Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock, par value

$ 0.01

Preferred stock, shares issued

790

Preferred Stock, original issue discount

5.00%

Preferred Stock, purchase price per share

$ 10,000

Gross proceeds from issuance of preferred stock

$ 7,500,000

Preferred Stock, conversion price

$ 10

Dividend rate

8.00%

Face value

$ 10,000

Payable of dividends of common stock, description

Dividends were paid either in cash or in shares of common stock at the Company’s sole discretion and were valued at (i) if there was no Trigger Event (as defined below), (A) 95.0% of the average of the 5 lowest individual daily volume weighted average prices of the common stock on the Trading Market during the applicable Measurement Period, which may be non-consecutive, less $0.50 per share of common stock, not to exceed (B) 100% of the lowest sales price on the last day of such Measurement Period less $0.50 per share of common stock or (ii) following any Trigger Event, (A) 80.0% of the lowest daily volume weighted average price during any Measurement Period for any conversion by Holder, less $1.00 per share of common stock, not to exceed (B) 80.0% of the lowest sales price on the last day of any Measurement Period, less $1.00 per share of common stock.

Proceeds from the issuance of preferred stock, net of issuance costs

2,800,000

Series A Redeemable Convertible Preferred Stock [Member] | First Amendment to Preferred Stock Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Redeemable convertible preferred stock reclassed from temporary to permanent equity

$ 0

Common Stock [Member] | Distribution Of Marketable Securities To Stockholders As Dividends [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of redeemable convertible preferred stock, shares

518,784

Common Stock [Member] | Initial Conversion Notices [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of redeemable convertible preferred stock, shares

1,025,499

Common Stock [Member] | January 4th Conversion Notice and Initial Conversion Notices [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of redeemable convertible preferred stock, shares

246,036

162,706

Series A Preferred Stock Initial Preferred Stock Conversion [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Proceeds from the issuance of preferred stock, net of issuance costs

$ 4,400,000

Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of stock options granted

1,100,000

Number of restricted stock units granted

791,173

Amended Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock available for issuance

2,400,000

Minimum [Member] | Series A Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Conversion of preferred stock, description

The Company was prohibited from issuing shares of common stock upon conversion of the Series A Preferred Stock if, as a result of the conversion, the holder, together with its affiliates, would beneficially own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, subject to adjustment up to 9.99% upon 61 days’ notice from the investor,

Percentage of common stock beneficially held by holder together with affiliates upon conversion

4.99%

Maximum [Member] | Series A Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock issued and outstanding subject to adjustment upon conversion

9.99%

Employee Stock Option [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of the options being expensed, service period

1 year

Employee Stock Option [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of the options being expensed, service period

3 years

Controlled Equity Offering Sales Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate offering price of common stock

$ 25,000,000

Shares of common stock issued

380,011

Common stock issued price, net of issuance costs

$ 4,600,000

Equity Purchase Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate offering price of common stock

$ 45,000,000

Shares of common stock issued

324,465

Common stock issued price, net of issuance costs

$ 4,800,000

Equity Transactions and Share38

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Employees and Directors (Detail) - Employees and Directors [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Options, Outstanding, Beginning | shares	102,552
Number of Options, Cancelled | shares	(8,686)
Number of Options, Outstanding, Ending | shares	93,866
Number of Options, Exercisable, Ending | shares	78,366
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 40.10
Weighted Average Exercise Price, Cancelled | $ / shares	49.25
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	39.25
Weighted Average Exercise Price, Exercisable, Ending | $ / shares	$ 39.79
Weighted Average Remaining Contractual Life (In Years), Outstanding Balance	5 years 6 months
Weighted Average Remaining Contractual Life (In Years), Exercisable Balance	5 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding Balance | $	$ 0
Aggregate Intrinsic Value, Exercisable Balance | $	$ 0

Equity Transactions and Share39

Equity Transactions and Share-Based Compensation - Schedule of Stock Options Activity by Other than Employees and Directors (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Options and Warrants, Granted	0	0	0	0
Other Than Employees and Directors Warrants [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Options, Outstanding, Beginning			1,793,981
Number of Options, Outstanding, Ending	1,793,981		1,793,981
Number of Options, Exercisable, Ending	1,793,981		1,793,981
Weighted Average Exercise Price, Outstanding, Beginning			$ 12.68
Weighted Average Exercise Price, Outstanding, Ending	$ 12.68		12.68
Weighted Average Exercise Price, Exercisable, Ending	$ 12.68		$ 12.68
Weighted Average Remaining Contractual Life (In Years), Outstanding Balance			8 years 9 months 18 days
Weighted Average Remaining Contractual Life (In Years), Exercisable Balance			8 years 9 months 18 days

Equity Transactions and Share40

Equity Transactions and Share-Based Compensation - Summary of Activity Related to Awards of Restricted Stock and Restricted Stock Units (Detail) - Restricted Stock Awards and Units [Member]	6 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested, Beginning balance | shares	882,948
Number of Restricted Stock Awards, Granted | shares	313
Number of Restricted Stock Awards, Vested | shares	(103,087)
Number of Restricted Stock Awards, Cancelled | shares	(94,159)
Number of Restricted Stock Awards, Unvested, Ending balance | shares	686,015
Weighted Average Grant Date Fair Value, Unvested, Beginning Balance | $ / shares	$ 15.41
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.78
Weighted Average Grant Date Fair Value, Vested | $ / shares	29.33
Weighted Average Grant Date Fair Value, Cancelled | $ / shares	7.33
Weighted Average Grant Date Fair Value, Unvested, Ending Balance | $ / shares	$ 14.42

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Property Plant And Equipment [Abstract]
Building	$ 32,362	$ 32,362
Machinery and equipment	20,090	19,537
Computer software	2,986	2,986
Furniture and fixtures	792	1,386
Construction in progress	13,385	13,870
Land	2,036	2,036
Leasehold improvements	349	437
Property, plant and equipment, gross	72,000	72,614
Less: accumulated depreciation and amortization	(19,691)	(17,841)
Property, plant and equipment, net	$ 52,309	$ 54,773

Property, Plant and Equipment42

Property, Plant and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Asset impairment charge	$ 0	$ 26,600,000	$ 0	$ 0	$ 0
Interest capitalized	0		700,000	0	1,400,000
Property, Plant and Equipment [Member]
Property Plant And Equipment [Line Items]
Depreciation	$ 1,000,000		$ 2,700,000	$ 1,400,000	$ 3,000,000

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	6 Months Ended
	Dec. 31, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 9,423
Foreign currency translation	(287)
Ending Balance	$ 9,136

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Payables And Accruals [Abstract]
Accrued payroll and other employee related expenses	$ 3,109	$ 2,755
Accrued cost related to equipment	1,320	2,623
Accrued transaction costs	4,000	5,000
Accrued professional fees	964	2,010
Accrued other	6,501	1,322
Total accrued expenses	$ 15,894	$ 13,710

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2016	Aug. 01, 2016	May 27, 2016
Payables And Accruals [Abstract]
Accrued other liability related to settlement of putative class actions and derivative complaints	$ 5	$ 0.6	$ 4.4

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Long-term debt	$ 127,282	$ 105,760
Less: unamortized debt discounts and issuance costs	(1,177)	(646)
Long-term debt	126,105	105,114
Less: current portion of long-term debt	(702)	(669)
Noncurrent portion of long-term debt	125,403	104,445
Royalty Agreement Liability [Member]
Debt Instrument [Line Items]
Long-term debt	5,464	5,120
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]
Debt Instrument [Line Items]
Long-term debt	1,948	1,977
Term Loan [Member] | 10.25% Term Loan, Due March 2020 [Member]
Debt Instrument [Line Items]
Long-term debt	64,303	57,227
Senior Secured Convertible Notes [Member] | 6.00% Senior Secured Convertible Note, Due February 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	43,428	29,066
Mortgage Loan [Member] | 6.00% Mortgage Loan, Due December 2031 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 12,139	$ 12,370

Long-Term Debt - Components o47

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended
	Dec. 31, 2016
10.25% Term Loan, Due March 2020 [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	10.25%
Long-term debt, due date	Mar. 12, 2020
6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	6.00%
Long-term debt, due year and month	2023-02
6.00% Mortgage Loan, Due December 2031 [Member] | Mortgage Loan [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	6.00%
Long-term debt, due year and month	2031-12
5.00% Commonwealth of Pennsylvania Financing Authority Loan, Due January 2021 [Member]
Debt Instrument [Line Items]
Long-term debt, percentage	5.00%
Long-term debt, due year and month	2021-01

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail)

Dec. 20, 2016USD ($)

Oct. 24, 2016USD ($)

Jul. 28, 2016LetterAgreement

Feb. 29, 2016USD ($)$ / shares

Feb. 22, 2016USD ($)$ / sharesshares

Mar. 12, 2014USD ($)

Oct. 31, 2010USD ($)Note

Dec. 31, 2010USD ($)

Mar. 31, 2016USD ($)

Dec. 31, 2016USD ($)$ / shares

Jun. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Debt Instrument [Line Items]

Repayment premium on unpaid principle amount of loans

10.00%

Percentage of repayment of debt from proceeds on sale of assets and casualty events

100.00%

Gain on extinguishment of debt

$ 2,900,000

Proceeds from the issuance of note

$ 15,000,000

Aggregate initial principal amount of debt

127,282,000

$ 105,760,000

Mortgage loans, amount

126,105,000

105,114,000

Chairman and Chief Executive Officer [Member]

Debt Instrument [Line Items]

Current portion of long-term debt

$ 600,000

First National Bank [Member]

Debt Instrument [Line Items]

Required to maintain a cash balance under financial covenants

5,000,000

Debt service reserve account

2,400,000

Minimum balance in debt service reserve account

$ 1,600,000

Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Royalty percentage on first $50 million of net sales

4.52%

Royalty percentage on second $50 million of net sales

1.75%

Royalty percentage on net sales in excess of $100 million

0.438%

Agreement buy-out date

Mar. 12, 2018

Agreement buy-out increases date, Description

On March 13, 2017, the buy-out amount increases to approximately $33.5 million, and on March 13, 2018, the buy-out amount increases up to a maximum of approximately $37.2 million.

Agreement, commencement date

Mar. 12, 2014

Agreement, expiration date

Mar. 12, 2024

Senior Secured Convertible Notes [Member] | Counterparty [Member] | Conversion Rate Floor Price [Member]

Debt Instrument [Line Items]

Debt instrument convertible, conversion price | $ / shares

$ 12.50

Mortgage Loan [Member] | First National Bank [Member]

Debt Instrument [Line Items]

Number of mortgage loans | Note

2

Maximum [Member] | Chairman and Chief Executive Officer [Member]

Debt Instrument [Line Items]

Repayments of loan

$ 100,000

Credit Agreement [Member]

Debt Instrument [Line Items]

Committed principal amount of term loan

$ 70,000,000

Warrants to repurchase common stock | shares

1,673,981

Exercise price of warrants | $ / shares

$ 12.50

Credit Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Required to maintain a cash balance under financial covenants

$ 3,000,000

10.25% Term Loan, Due March 2020 [Member] | Term Loan [Member]

Debt Instrument [Line Items]

Interest rate per annum

9.25%

Additional interest rate on LIBOR

1.00%

Term loan, interest rate terms

The Loans bear interest at 9.25% per annum plus the greater of three-month LIBOR or 1.0%.

Interest payable description

January 1, 2016 through February 22, 2018

Term loan, default interest rate, fixed percentage

14.25%

Term loan, default interest rate, variable percentage

1.00%

Term loan ,default interest rate terms

A default interest rate of 14.25% per annum plus the greater of three-month LIBOR or 1.0%

Term loan maturity date

Mar. 12, 2020

Long-term debt, percentage

10.25%

Aggregate initial principal amount of debt

$ 64,303,000

57,227,000

Amended Credit Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Repayment premium on unpaid principle amount of loans

10.00%

Eighth Amendment to Credit Agreement [Member]

Debt Instrument [Line Items]

Warrants to repurchase common stock | shares

1,673,981

Exercise price of warrants | $ / shares

$ 12.50

Debt, fair value

$ 51,300,000

4.52 % [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Net sales

50,000,000

1.75 % [Member] | Minimum [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Net sales

50,000,000

1.75 % [Member] | Maximum [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Net sales

100,000,000

0.438 % [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Net sales

100,000,000

March 13, 2018 [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Increase in buy-out amount

37,200,000

December 31, 2016 [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Buy-out amount

27,700,000

March 2017 [Member] | Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Buy-out amount

33,500,000

Amended Royalty Agreement [Member]

Debt Instrument [Line Items]

Royalty agreement liability

7,000,000

$ 5,500,000

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member]

Debt Instrument [Line Items]

Proceeds from the issuance of note

30,000,000

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member] | 2017 Convertible Note [Member]

Debt Instrument [Line Items]

Maximum amount of notes purchased

15,000,000

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Counterparty [Member] | 2018 Convertible Note [Member]

Debt Instrument [Line Items]

Maximum amount of notes purchased

$ 10,000,000

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Senior Secured Convertible Notes [Member]

Debt Instrument [Line Items]

Long-term debt, percentage

6.00%

Long-term debt, due year and month

2023-02

Aggregate initial principal amount of debt

$ 43,428,000

29,066,000

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Senior Secured Convertible Notes [Member] | Counterparty [Member]

Debt Instrument [Line Items]

Long-term debt, percentage

6.00%

Long-term debt, due year and month

2023-02

6.00% Senior Secured Convertible Note, Due February 2023 [Member] | Maximum [Member] | Senior Secured Convertible Notes [Member] | Counterparty [Member]

Debt Instrument [Line Items]

Principal amount of debt

$ 55,000,000

Counterparty Letter Agreement [Member]

Debt Instrument [Line Items]

Number of letter agreements | LetterAgreement

2

Right to terminate conversion limit period

75 days

Counterparty Letter Agreement [Member] | Senior Secured Convertible Notes [Member] | 2017 Convertible Note [Member]

Debt Instrument [Line Items]

Principal amount of debt

$ 10,000,000

Proceeds from the issuance of note

10,000,000

Financing fee

600,000

Aggregate initial principal amount of debt

$ 10,600,000

Counterparty Letter Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Percentage of outstanding common stock conversion limit

10.00%

December 2016 Convertible Note [Member] | Senior Secured Convertible Notes [Member] | 2017 Convertible Note [Member]

Debt Instrument [Line Items]

Principal amount of debt

$ 5,000,000

Proceeds from the issuance of note

5,000,000

Aggregate initial principal amount of debt

$ 5,000,000

Outstanding Counterparty Notes [Member] | Senior Secured Convertible Notes [Member]

Debt Instrument [Line Items]

Term loan maturity date

Feb. 22, 2023

Long-term debt, percentage

6.00%

Principal and loan prepayment prior notice period

15 days

Non-cash repayments relating to development and customization fees

$ 2,300,000

Excess of other Indebtedness

1,000,000

Excess of adjustment, long-term debt

$ 1,000,000

Debt instrument, redemption percentage of principal amount redeem

101.00%

Derivative liability, market value

$ 500,000

Outstanding Counterparty Notes [Member] | Senior Secured Convertible Notes [Member] | Collateral [Member] | Conversion Rate Floor Price [Member]

Debt Instrument [Line Items]

Debt instrument convertible, conversion price | $ / shares

$ 12.50

Outstanding Counterparty Notes [Member] | Senior Secured Convertible Notes [Member] | 2016 Convertible Note [Member]

Debt Instrument [Line Items]

Derivative liability, fair value

$ 1,700,000

Outstanding Counterparty Notes [Member] | Senior Secured Convertible Notes [Member] | October 2016 Convertible Note [Member]

Debt Instrument [Line Items]

Derivative liability, fair value

100,000

Outstanding Counterparty Notes [Member] | Maximum [Member] | Senior Secured Convertible Notes [Member] | December 2016 Convertible Note [Member]

Debt Instrument [Line Items]

Derivative liability, fair value

$ 100,000

September Counterparty Letter Agreement [Member]

Debt Instrument [Line Items]

Agreement, commencement date

Sep. 29, 2016

Agreement, expiration date

Jul. 1, 2017

Mortgage Loan 1 [Member] | First National Bank [Member]

Debt Instrument [Line Items]

Interest rate per annum

6.00%

Mortgage loans, amount

$ 14,250,000

Mortgage Loan 2 [Member] | First National Bank [Member]

Debt Instrument [Line Items]

Mortgage loans, amount

$ 3,750,000

6.00% Mortgage Loans, Due October 2020 [Member] | Mortgage Loan [Member] | First National Bank [Member]

Debt Instrument [Line Items]

Long-term debt, due year and month

2020-10

6.00% Mortgage Loan, Due December 2031 [Member] | First National Bank [Member]

Debt Instrument [Line Items]

Long-term debt, due year and month

2031-12

Amount of loans guaranteed by U.S. Department of Agriculture

$ 8,000,000

6.00% Mortgage Loan, Due December 2031 [Member] | Mortgage Loan [Member]

Debt Instrument [Line Items]

Long-term debt, percentage

6.00%

Long-term debt, due year and month

2031-12

Aggregate initial principal amount of debt

$ 12,139,000

$ 12,370,000

Keystone [Member]

Debt Instrument [Line Items]

Interest rate per annum

5.00%

Long-term debt, due year and month

2021-01

Loan amount for financing for land and construction of current manufacturing facility

$ 2,250,000

Net Loss Per Share - Net Loss P

Net Loss Per Share - Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Numerator
Net loss	$ (15,309)	$ (25,423)	$ (33,282)	$ (51,287)
Deemed dividend on Series A Preferred Stock	0	(1,047)	0	(1,047)
Net loss attributable to common stock holders	$ (15,309)	$ (26,470)	$ (33,282)	$ (52,334)
Denominator
Weighted average number of shares used to compute basic net loss per share	16,698,329	13,377,229	16,672,595	12,915,014
Effect of dilutive options to purchase common stock	0	0	0	0
Weighted average number of shares used to compute diluted net loss per share	16,698,329	13,377,229	16,672,595	12,915,014
Basic and diluted net loss per share	$ (0.92)	$ (1.98)	$ (2)	$ (4.05)

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental shares in case of profit for calculating diluted earnings per share	0	0	0	0
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share excluded from calculation of basic and diluted net loss per share	729,434	1,007,211	789,889	1,035,368
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share excluded from calculation of basic and diluted net loss per share	1,887,797	333,189	1,887,797	319,929
Incremental shares in case of profit for calculating diluted earnings per share	0	0	0	0
2016 Convertible Note [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share excluded from calculation of basic and diluted net loss per share			3,605,069

Contingencies - Additional Info

Contingencies - Additional Information (Detail)	Oct. 24, 2016Defendant	Sep. 02, 2016USD ($)	Aug. 17, 2016USD ($)	May 27, 2016USD ($)PlaintiffDefendant	Mar. 24, 2016USD ($)	Aug. 01, 2016USD ($)Defendant	Dec. 31, 2016USD ($)
Contingencies [Line Items]
Number of putative class actions filed | Plaintiff				2
Number of defendants | Defendant	3			6
Receivable from insurance carrier				$ 4,400,000		$ 600,000
Liability to claimants				$ 4,400,000		$ 600,000	$ 5,000,000
Received assessment for sales and use taxes							300,000
Restricted cash account as collateral for sales and use taxes assessment							$ 300,000
Current or Former Directors and/or Officers [Member]
Contingencies [Line Items]
Number of defendants | Defendant						11
Edward Fine Complaint [Member]
Contingencies [Line Items]
Damages sought, value					$ 288,000
Kahle | Kahle Automation, S.r.l. [Member]
Contingencies [Line Items]
Damages sought, value			$ 4,200,000
Kahle | Kahle Automation, S.r.l. [Member] | Bank Fees
Contingencies [Line Items]
Damages sought, value			900,000
Kahle | Kahle Automation, S.r.l. [Member] | Lost Profits
Contingencies [Line Items]
Damages sought, value			$ 800,000
Second Biodel Agreement [Member]
Contingencies [Line Items]
Option to purchase asset associated with First Biodel Agreement		$ 1,500,000
Option exercisable term		6 months

Revenue - Additional Informatio

Revenue - Additional Information (Detail)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)Customer	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)Customer	Dec. 31, 2016USD ($)Customer	Dec. 31, 2015USD ($)Customer
Concentration Risk [Line Items]
Revenue			$ 2,340,000		$ 4,499,000	$ 4,053,000	$ 7,686,000
Revenue recognized related to substantive milestones			600,000		2,100,000	1,000,000	3,900,000
Amgen Inc. [Member]
Concentration Risk [Line Items]
Non-refundable license fee amount				$ 20,000,000	15,000,000
Amgen Inc. [Member] | First License Fee
Concentration Risk [Line Items]
License revenue recognized			$ 200,000			300,000
Patent life expiration year			2,032
Customer Agreements [Member]
Concentration Risk [Line Items]
Revenue			$ 1,500,000		2,400,000	2,700,000	3,800,000
Master Services and Supply Agreement [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones			$ 600,000		900,000	1,000,000	1,500,000
Initial up-front payment						1,100,000	1,100,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Development and Delivery of Components for Human Factor Study [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones						400,000
Remaining substantive milestones revenue							300,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Completion of Testing of Assembly Equipment [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		$ 400,000				400,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Completion of Filling Process of Clinical Devices [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		300,000				$ 300,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Delivery of Containers for Filling Process [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue	$ 400,000	400,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Delivery of Devices for Clinical Studies [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue	$ 300,000	300,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Development and Delivery of Complete System Layout [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones							600,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Development and Delivery of Feasibility Devices for Testing [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue							600,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Development and Delivery of Clinical Production Process [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		600,000
Master Services and Supply Agreement [Member] | Milestone One [Member] | Development and Delivery of Components for Human Factor Study One [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		400,000
Master Services and Supply Agreement [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones					0		400,000
Initial up-front payment							1,000,000
Master Services and Supply Agreement [Member] | Milestone Two [Member] | Development and Delivery of Feasibility Devices for Testing [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones							400,000
Master Services and Supply Agreement [Member] | Milestone Two [Member] | Delivery of Design Transfer for Device and Related Filling Equipment and Fixtures [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		600,000
Master Services and Supply Agreement [Member] | Milestone Two [Member] | Commissioning of Pilot Line [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue		$ 300,000
Feasibility Agreement One [Member] | Milestone One [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones					1,200,000		1,700,000
Initial up-front payment							100,000
Feasibility Agreement One [Member] | Milestone One [Member] | Development and Delivery of Additional Human Factor Stimuli and Report on Updated Product Requirements [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones							500,000
Feasibility Agreement One [Member] | Milestone One [Member] | Development and Delivery of Semi-functional Prototypes And Related Feasibility Product Requirement and Risk Management Reports [Member]
Concentration Risk [Line Items]
Remaining substantive milestones revenue							1,200,000
Feasibility Agreement One [Member] | Milestone Two [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones					$ 0		300,000
Initial up-front payment							500,000
Remaining substantive milestones revenue							0
Feasibility Agreement One [Member] | Milestone Two [Member] | Development And Delivery Of Summary Report Related To Testing And Documentation Activities [Member]
Concentration Risk [Line Items]
Revenue recognized related to substantive milestones							$ 300,000
Consolidated Revenue [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Number of customers accounted for consolidated revenue | Customer			4		3	3	4
Consolidated Revenue [Member] | Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			41.00%		39.00%	41.00%	32.00%
Consolidated Revenue [Member] | Sales Revenue, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			37.00%		30.00%	28.00%	28.00%
Consolidated Revenue [Member] | Sales Revenue, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			12.00%		25.00%	24.00%	25.00%
Consolidated Revenue [Member] | Sales Revenue, Net [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			10.00%				11.00%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 2,147	$ 3,351
Derivative liability	457	347
Royalty Agreement Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Fair Value Measurements	5,464	5,120
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	2,147	3,351
Derivative liability	457	347
Significant Unobservable Inputs (Level 3) [Member] | Royalty Agreement Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Fair Value Measurements	$ 5,464	$ 5,120

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Changes in Fair Value of Level 3 Financial Instruments (Detail) $ in Thousands	6 Months Ended
	Dec. 31, 2016USD ($)
Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 3,351
Increase (decrease) in liability	(1,204)
Ending balance	2,147
Derivative Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	347
Liability recognized on new debt issued during period	172
Increase (decrease) in liability	(62)
Ending balance	457
Royalty Agreement Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	5,120
Cash payments	(41)
Increase (decrease) in liability	385
Ending balance	$ 5,464

Sublease - Additional Informati

Sublease - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Sublease [Line Items]
Non cash charge relating to sublease				$ 709
Depreciation and amortization		$ 996	$ 1,422	2,686	$ 2,965
Expense incurred to accrete the value of sublease liability				300
Sublease Costs [Member]
Sublease [Line Items]
Non cash charge relating to sublease				709
Depreciation and amortization				$ 600
King of Prussia Offices [Member]
Sublease [Line Items]
Subleased commenced date	Oct. 1, 2016
Subleased expiration date	Mar. 31, 2019
Subleased portion rent receivable	$ 1,300
Subleased rent payable	1,900
Additional subleased rent receivable over renewal term	1,900
Subleased portion rent payable upon exercises of renewal option	$ 2,500
Subleased renewal commenced date	Apr. 1, 2019
Subleased renewal expiration date	Jun. 30, 2022

Sublease - Summary of Liability

Sublease - Summary of Liability and Cash Costs Paid or Settled in Connection With Sublease, Total Charges Expected to be Incurred and Cumulative Charges Incurred to Date (Detail) - Sublease Costs [Member] $ in Thousands	6 Months Ended
	Dec. 31, 2016USD ($)
Restructuring Cost And Reserve [Line Items]
Initial liability measurement	$ 909
Costs incurred and charges to expenses	17
Costs paid or settled	(206)
Ending balance	720
Total charges expected to be incurred	1,599
Cumulative charges incurred to date	$ 1,310

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Feb. 29, 2016USD ($)	Jul. 23, 2015USD ($)	Jul. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)Executive	Dec. 31, 2015USD ($)	Jun. 30, 2016USD ($)	Sep. 30, 2015USD ($)
Related Party Transaction [Line Items]
Restricted cash				$ 2,700,000		$ 2,700,000		$ 2,400,000
Proceeds from former CEO loan							$ 600,000
Shortall Funds
Related Party Transaction [Line Items]
Restricted cash								$ 2,264,475
Amount disbursed to third parties		$ 1,351,553
Chairman and Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Current portion of long-term debt									$ 600,000
Chairman and Chief Executive Officer [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Repayments of loan	$ 2,000
Shortall Fund Transfers [Member]
Related Party Transaction [Line Items]
Payment of former CEO loan							6,000
Proceeds from former CEO loan				0	$ 0	0
Mr. Shortall [Member]
Related Party Transaction [Line Items]
Funds transmitted to a third party				0	0	0	12,000
Unreimbursed personal expenses				0	200	0	600
Mr. Shortall [Member] | General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Funds transmitted to a third party				0	0	0	12,000
Unreimbursed personal expenses				$ 0	$ 200	$ 0	$ 600
Executive Officers [Member]
Related Party Transaction [Line Items]
Number of executive officers | Executive						2
Executive Officers [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Aggregate withholding taxes amount			$ 126,000
Executive Officers [Member] | Maximum [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Withholding payment period						28 days
Executive Officers [Member] | Minimum [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Withholding payment period						18 days